The role of the P2 purine transporter in drug uptake and resistance in trypanosomes by Stewart, Mhairi L
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The Role of the P2 Purine Transporter in Drug 
Uptake and Resistance in TVvpanosomes
K- Mhairi L. Stewart
Division of Infection and Immunity 
Institute of Biomedical and Life Sciences
This thesis is submitted for the degree of Doctor of Philosophy
Faculty of Biomedical and Life Sciences 
University of Glasgow 
March 2003
ProQuest Number: 10390795
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is d e p e n d e n t upon the quality of the copy subm itted.
In the unlikely e v e n t that the author did not send a c o m p le te  manuscript 
and there are missing p a g e s , these will be n oted . Also, if material had to be rem oved,
a n o te  will ind icate the deletion .
uest
ProQuest 1 0 3 9 0 7 9 5
Published by ProQuest LLO (2 0 1 7 ) .  Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C o d e
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 4 8 1 0 6 -  1346
[ G la s g o w   ^
GMVERSITY L^IBRARY:
/ J ( ? 6 ?  
c o p j - 2
Declaration
The results presented in this thesis are my own work, except where there is a statement to the 
contrary.
Mhairi L. Stewart
Abstract
Human African Tiypanosomiasis (HAT), caused by the parasitic trypanosomatids T. b. 
gambiense and T. b. rhodesiense, is endemic in over 36 countries in sub-Saharan Africa. 
Estimates place the numbers of infected individuals at around 500,000 with a frrrther 60 
million at risk. Treatment for HAT is available, although all the drugs in use have problems 
with availability, administration and disease stage specificity, and most cause very severe side 
effects. The arsenical based trypanocides are extremely toxic, causing death due to treatment 
in up to 10% of patients.
Reports of drug resistance in the field are wide spread. A few reports have suggested the 
involvement of the P2 transporter in the development of drug resistance. Point mutations 
within TbATI, which encodes the P2 transporter, have been linked to drug resistant isolates in 
the field, and the loss of function of P2, through various molecular processes are a feature of 
laboratory derived drug resistant cell lines. However, the loss of P2 transport in a ATbatl cell 
line does not produce the high levels of resistance seen in laboratory derived drug resistant cell 
lines, and many isolates from relapse patients have shown no difference in TbATI indicating 
that the situation in the field regarding resistance and P2 transport is very complicated, and 
that other routes to resistance exist. Nonetheless, an exponential increase in the prevalence and 
distribution of HAT, coupled with an increased incidence of reported drug resistance, makes 
the development of new trypanotoxic compounds vital.
The exploitation of the P2 purine transporter as a parasite-specific entry point for new 
trypanocidal compounds has been investigated in this thesis. The P2 transporter is ideal for 
this approach to drug design due to its high affinity for substrates carrying the primary 
recognition moti^ H2N-C(Ri)=N-R2, the lack of any similar motif on mammalian purine 
transporters and its natural substrates being at very low concentrations within the bloodstream 
of the host. Melamine and benzamidine groups, which cany the recognition motif for the P2 
transporter, were attached to potentially cytotoxic moieties (polyamine analogues, HIV gpl20 
binding mimetics, nitrofuran and nitroimidazole compounds) in order to target them 
specifically to the parasite transporter and hence the parasite.
in
All compounds carrying a melamine or benzamidine group were able to block the uptake of 
radiolabelled adenosine (a natural substrate of P2) to some degree. Toxicity varied, but some 
compounds were extremely trypanotoxic in vitro, and one nitrofiiran is active in vivo and 
could represent a promising lead compound. In vitro toxicity experiments using a ATbatl (P2 
knockout) cell line, reveal no innate resistance to P2 recognition motif bearing compounds in 
these cells, suggesting that the P2 transporter is not crucial for the toxic actions of these 
compounds, allaying fears over the development of resistance and cross resistance to other 
trypanocides through the loss of P2.
The role of the P2 transporter in the development of drug resistance was investigated in a 21 
equiperdum cell line (P) and a Berenil resistant cell line (PBR) derived from it that had been 
reported to have a P2 transport component with greatly reduced affinity for adenosine. 
Sequencing results indicate that TbATI in T equiperdum P exists as two alleles, whereas the 
T. equiperdum PBR cell line only contains sequence corresponding to one. Additionally, the T 
equiperdum PBR cell line lacks any TbATI transcript detectable by Northern blot, which 
suggests that this loss of heterozygosity in T equiperdum PBR has resulted in a lack of 
transcription of the gene, and a loss of P2 transport activity. An adenine sensitive adenosine 
transport component was identifiable m this cell line as well as in the ATbatl cell line, 
suggesting the presence of an, as yet unidentified, low affinity adenosine transporter in 
tiypanosomes.
Finally, as loss of P2 has been seen to contribute to drug resistance in both laboratory derived 
cell lines and field isolates, a quick and simple test has been developed that is capable of 
identifying cells lacking the P2 transporter, and are therefore tolerant to pharmacologically 
relevant levels of diamidme and arsenical trypanocides. This simple test could be adapted for 
use in the field either for research purposes, or by clinical staff, with the aim of identifying 
patients with drug resistant tiypanosomiasis, and tailoring their treatment accordingly.
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Chapter I. Introduction.
1*1 Current Situation of Human African Trypanosomiasis (HAT)
At the beginning of the 1900’s the incidence of HAT was extremely high. One review places 
the number of human cases of trypanosomiasis at over 1 million, with over 250,000 reported 
deaths in Uganda (Seed 2000). By the 1960’s and early 1970’s this figure was greatly reduced 
due to the use of insect vector control strategies (use of insecticides and clearing of 
vegetation), the removal of animal reservoirs (by hunting and culling) and the screening and 
treatment of infected people. The number of infected individuals was placed at around 10,000 
-  20,000 during this period.
Due to the lack of screening and diminished use of insecticides targeted against the tsetse fly 
this number has risen over the intervening years to the present day situation where 
approximately 60 million people live in endemic areas in 36 countries in sub-Saharan Africa 
(Barrett 1999). 200 discrete endemic foci have been described, and epidemics have emerged in 
Sudan, Uganda, Angola and the Democratic Republic of Congo (DRC), (Figure 1.1). 36,000 
cases of HAT were reported in 1998, however, as only 5-10 % of the population was screened 
the figure is considered to be closer to, and more likely greater than, 300,000 persons infected 
in that year (WHO, Report of a WHO Expert Committee, 1998).
The current epidemics reported in Angola, the DRC, southern Sudan and Uganda are mostly 
due to infection by T. b. gambiense. In the DRC in 1977 there were 3,818 new cases reported 
per year. This rose to 19,340 new cases reported in 1994, according to World Heath 
Organisation figures (WHO, Report of a WHO Expert Committee, 1998). Just as dramatic is 
the rise in reported new cases in Uganda from 52 in 1970, to more than 1,500 in 1994. The 
prevalence of infection in southern Sudan rose by 20 %, and areas of Angola now have a 
prevalence of 60 %. Many of the epidemic areas are inaccessible due to war, and up to 50 % 
of those infected are in the secondary stage of HAT (Legros et al. 2002; Seed 2000).
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African Trypanosomiasis  y - S
Figure 1.1 Distribution of Human African Trypanosomiasis.
Reproduced from http://www.who.int/emc/diseases/tryp/trypanogeo.html
War in an endemic area can increase the spread of trypanosomiasis, especially the gambiense 
form of the disease. The primary stage of gambiense sleeping sickness can last for many 
months, even years, with just general symptoms of malaise. In this time an infected person can 
act as a walking reservoir, capable of spreading disease. Many reftigees migrating from war- 
torn epidemic areas carry trypanosomiasis with them to new areas where tsetse flies native to 
this new environment spread the infection. The outbreaks in Uganda, for example, are partly 
due to the migrations of peoples out of southern Sudan for this reason (Kuzoe 1993). This 
exponential increase in the prevalence and distribution of HAT, coupled with an increased 
incidence of reported drug resistance, has sparked an increase in research activity concerned 
with the discovery of new treatments for HAT.
1.2 The Trvpanosome
1.2.1 Taxonomy
Trypanosomes are protozoons of the order Kinetoplastida, family Trypanosomatidae. 
Trypanosomatids include the genus Leishmania, species and subspecies of which are
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responsible for human diseases such as visceral leishmaniasis (L. donovani), cutaneous and 
mucocutaneous leishmaniasis (X. braziliensis), and difiuse cutaneous leishmaniasis 
(X. mexicand). The genus Trypanosoma can be further divided into two groups of infective 
parasites, the stercoraria and the salivaria. The stercoraria include the human infective species 
T. cruzi, the causative agent of Soutli American trypanosomiasis. The human infective 
T. brucei gambiense and T. brucei rhodesiense, are salivarian parasites of the subgenus 
Trypanozoon (Figure 1.2), which also contains the animal infective species T. equiperdum, 
T evansi and T brucei
Subkingdom
Phylum
Subphylum
Class
Order
Suborder
Family
Genus
Protozoa 
Sarcomastigophora 
Mastigophora 
Zoomastigopliora 
Kinetoplastida 
Trypanosomatina 
Trypanosomatidiae 
Tiypanosoma
Subgenus Herpetosoma Mcgaliypmmm Schizolryiximim
Species r  (H.) lewisi T. (M.) Iheileri T. (S.) cnizi
T. (H.) musculi T. (M.J nieloptiagliim T. (S.) (UoDlsU
T. (H.) microH
Stercoraria
DitUonelh
T. (D.) vhuK 
T. (D.) tmiforme
Nannomoms
T. (N.) cmgotense 
T. (N.) simiae
Tiypaiiozooit
T. ÇP.) eipii/Krcliim 
T. Cl') evaiisl 
T. Cl') b. brucei 
T. Cl') b. gambiense 
T. Cl'-) b. rhodesiense
Pycmm oms  
T. (P.) suis
Salivaria
Figure 1.2 Classification of Trypanosomes. 
From WHO, Report o f  a WHO Expert Committee, 1998.
T. brucei is regarded as a collection of subspecies which include the human infective species 
and the animal infective T b. brucei. These three subspecies are morphologically 
indistinguishable, but can be distinguished by isoenzyme analysis and restriction enzyme 
fragment length polymorphism (RFLP) (Gibson 2002; Kanmogne et al, 1996; Truc & 
Tibayrenc 1993).
T. b. rhodesiense and T. b. brucei are closely related, but T. b. rhodesiense are differentiated 
by their infectivity for humans. Rhodesiense parasites are able to withstand lysis by human 
semm due to the action of a serum resistance associated (SRA) gene (De Greef et al. 1992) 
expressed from a variant surface glycoprotein gene expression site (Hager & Hajduk 1997;
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Milner & Hajduk 1999). Human infective trypanosomes can be detected in auimal reservoirs 
by identification of the SRA gene (Welbum et al. 2001). T, b. rhodesiense and T. b. brucei can 
also be differentiated by minisatelhte marker analysis (MacLeod et al. 2000).
T. b. gambiense is characterised as a distinct group, but can be further divided ùito two 
categories based on the clinical presentation of the disease. The Type I group causes a disease 
pattern that shows classical, chronic, T. b. gambienseASkQ progression and Type II causes a 
more acute disease which is more like that caused by T. b. rhodesiense in development. Type 
II parasites give a negative result on polymerase chain reaction (PCR) analysis of the variant 
surface glycoprotein (VSG) gene Antat 11.17 (Bromidge et al. 1993), as did T. b. rhodesiense 
and T. b. brucei, and have shown different RFLP patterns to Type I cell lines (Agbo et al. 
2001).
1.2.2 Life Cycle
Figure 1.3 illustrates the life cycle of T. b. brucei, T. b. gambiense and T. b. rhodesiense, all of 
which are transmitted by an insect vector, the tsetse fly.
A fly becomes infected when it takes a blood meal firom an infected host. Within the insect’s 
midgut, the pre-adapted short-stumpy forms differentiate into elongated procyclic 
trypanosomes. These procyclic cells further differentiate in the hindgut into mesocyclic cells, 
which then migrate to the oesophagus and the mouthparts of the insect, eventually travelling 
up the salivaiy ducts to the salivary gland. In the salivary gland they proliferate rapidly as the 
epimastigote forms which are attached to the walls of the salivary gland by a flagellipodium, a 
dendritic outgrowth of the flagellum. Epimastigotes mature into the free living metacyclic 
forms, which are pre-adapted for life within the mammalian host. Metacyclic forms are then 
introduced into the mammalian bloodstream through the bite of the fly and undergo 
differentiation into the long slender bloodstream form (Vickerman 1985). The long slender 
form of the parasite divides within the mammalian bloodstream and undergoes antigenic 
variation (Turner 1999).
Chapter I. Introduction.
Antigenic variation refers to the ability of the population of infecting cells to change its major 
surface glycoprotein in order to evade the host’s immune system. The metacyclic cells that are 
introduced into the bloodstream are a mixed population, carrying different VSGs. As these 
cells differentiate into long slender bloodstream forms and divide, the host’s immune system is 
able to identify and mount a response to the predominant VSGs. At the same time a small 
subpopulation switch their dominant surfece antigen. Consequently, as the older populations 
of cells are eradicated, others are able to grow up before an immune response is mounted 
against them. As this process is repeated, a population of trypanosomes is able to evade the 
host’s immune system, and present a fluctuating parasitaemia within the bloodstream (Barry & 
McCulloch 2001).
MAMMAL
Figure 1.3 Life cvcle of Trypanosoma brucei. 
Illustration constructed by D , Barry, University o f  Glasgow.
When a population of long slender forms reaches a peak parasitaemia some of the cells 
differentiate into short stumpy forms. These cells are non-proliferative and are quickly 
eradicated from the mammalian host’s bloodstream, but are pre-adapted to continue the cycle
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of infection in the tsetse fly vector, whereas the proliferative long slender forms are destroyed 
in the midgut (Matthews 1999).
T. b. gambiense and T. b. rhodesiense are ordinarily transmitted by different species of tsetse 
fly, varying in their habitats. T. b. gambiense is transmitted by Glossina palpaUs and other 
related species which normally live along river banks. T. b. rhodesiense is transmitted by 
Glossina morsitans and related species, which are savannah dwelling species (WHO, World 
Health Report, 2002). Although their ranges can overlap, the nature of the vector species 
largely determines the distribution of the disease.
Other parasitic trypanosomes infective to mammals do not undergo cyclical transmission 
through an insect. T. evansi is a parasite of wild and domestic animals that has lost the ability 
to pass cyclically through an insect vector. Infections are carried to a new host by mechanical 
transmission on the mouthparts of biting insects. T. equiperdum has specialised even further 
and only infects equines and has no need of any insect ‘carrier’, but is instead transmitted 
during coitus (Stephen 1986).
1.2.3 The Trvpanosome Genome
Trypanosomes possess three different classes of nuclear chromosomes, the megabase 
chromosomes (1 Mb - >6 Mb), the intermediate chromosomes (200-900 kb) and the 
minichromosomes (50-150 kb). These chromosomes have been separated and identified by 
pulsed field gel electrophoresis as the chromosomes do not condense during mitosis. The 
haploid DNA content is approximately 35 Mb with up to 25 % variation between strains (El 
Sayed et al. 2000).
There are 11 pairs of megabase chromosomes, numbered I to XI according to their size. They 
are diploid, but homologous pairs are often different sizes. Southern hybridisation with various 
probes suggests that they carry a bloodstream form VSG expression site at one end, and a 
metacyclic VSG expression site at the other (El Sayed et al. 2000). Only one VSG expression 
site is active at any one time. The mechanisms for silencing the remaining sites, and for 
changing expression to other sites are not known, although the recent identification of an RNA
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polymerase I body, independent of the nucleolus, that associates with active expression sites 
might be of significance (Navarro & Gull 2001). Megabase chromosomes also carry 
housekeeping and trypanosome specific genes on their interior as well as large regions to 
which ribosomal inserted mobile elements (RIME) and ingi probes hybridise. These 
mgz/RIME regions vary in size and contribute greatly to the size polymorphism in megabase 
chromosomes (El Sayed et al. 2000).
Intermediate chromosomes vary in number and size, and their ploidy is uncertain. They 
contain few unique markers, but can carry telomere linked VSGs. It is possible that they act as 
a repository for VSG genes or VSG expression sites (El Sayed et al. 2000).
Minichromosomes may also provide a store for inactive VSG genes, as no other fimction has 
yet been identified for them. Up to 90 % of the chromosome consists of 177 bp repeats, which 
are separated from the telomeres by GC and AT rich repeats. Although some telomeres are 
linked to silent VSG expression sites, no active site on a minichromosome has been identified 
so far (Barry & McCulloch 2001).
In addition to their nuclear DNA, trypanosomes possess an interlinked network of DNA in 
their mitochondria, the kinetoplast, which consists of supercoiled minicircles (~ 1 kb) and 
maxicircles (~ 20 kb) and make up to 20 % of a trypanosome’s total DNA content. The 
maxicircles are the equivalent of mitochondrial DNA in other eukaryotic organisms, and the 
minicircles encode a series of guide RNAs. These serve as templates for the insertion and 
deletion of uridine residues in the maxicircle transcripts, a process known as RNA editing 
(Benne 1994). These modifications can be on a large scale, with more than half of the 
nucleotides in a reading fiume being added by this process (Feagin et al. 1988).
The sequencing of the T. brucei genome is underway. There are at least ten laboratories world­
wide contributing to this work, co-ordinated by the UNDP/World Bank/WHO Special 
Programme for Research and Training in Tropical Disease (TDR). This network aims to 
characterise further the T. brucei genome and provide an integrated facility open to all 
researchers working on T. brucei. The genome is considered to be around 90 % complete at 
the time of writing, with an expected completion date in 2004.
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1.3 Disease, Diagnosis and Treatment
1.3.1 Clinical Disease
HAT has two clinical phases, distinguished by the presence, or absence, of parasites within the 
central nervous system (CNS). The first stage of the disease is essentially a haemolymphatic 
phase where tlie parasites reside within the blood and lymphatic systems, as well as the extra 
cellular spaces outside of the CNS. Second stage disease occurs when trypanosomes invade 
the CNS establishing a meningoencephalitic infection (Enanga et al. 2002). T. b. gambiense 
and T. b. rhodesiense infections display somewhat similar symptoms, but the rhodesiense 
disease progresses much faster than the gambiense form, progressing to second stage disease 
and death within months or even weeks. Gambiense infections, on the other hand, can remain 
quiescent for many months, even years (WHO, Report of a WHO Expert Committee, 1998).
First stage disease presents no more specific symptoms than fever, severe headaches and joint 
and muscle pain. A chancre can develop at the site of the tsetse fly bite, and lymphadenopathy 
can occur, hi gambiense disease this is often confined to the posterior cervical lymph nodes 
(Winterbottom’s sign), but in rhodesiense disease it is more generalised. After the 
tiypanosomes migrate through the blood-brain barrier, neurological symptoms become 
apparent. This second stage of the disease can manifest itself in sleep disturbances (hence the 
common name ‘sleeping sickness’), confusion and disorientation and personality and 
behavioural changes. If left to develop further, there is a progressive loss of consciousness, 
which culminates in coma and death (WHO, Report of a WHO Expert Committee, 1998).
13.2 Diagnosis
Positive diagnosis of the disease, at all stages, is dependent on the identification of 
trypanosomes within the blood, lymphatic fluids or cerebrospinal fluids of patients. 
Parasitaemia can be extremely low, so concentration techniques are often used to help view 
the parasites. As the very early symptoms of the disease are not normally severe, and health 
care in most endemic areas is inadequate and sparse, patients are very rarely diagnosed in the
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early stages of infection. As a consequence most patients present themselves in the later stages 
of the disease when the parasite has already invaded the central nervous system (CNS).
That parasites have invaded the CNS, and the disease has progressed to the second stage, can 
be established by examining a sample of cerebrospinal fluid for trypanosomes. These can be at 
veiy low levels, and difficult to detect, so the presence of above normal numbers of leukocytes 
(> 5 cells/ml) within the CNS or high protein levels (> 37 mg/100 ml) is used as an indicator 
of CNS involvement (WHO, Report of a WHO Expert Committee, 1998).
1.3.3 Treatment
The drugs used to treat HAT are disease stage specific. Drugs used against the later stage of 
the disease can be very toxic or difficult to obtain and administer, and those used against the 
primary stage are ineffective against infections that have already invaded the CNS. Because of 
this, it is important to determine at what stage of disease the patient is presenting before 
treatment begins.
1.3.3.1 Treatment of Early Stage Disease
Suramin (Figure 1.4), which was first used in 1922 (Voogd et al. 1993), can be used to treat 
both gambiense and rhodesiense early stage infections. At physiological pH, Suramin, a 
polysulphonated naphthalene derivative, is highly charged with 6 negative charges. The drug 
binds to many serum components, including low density lipoprotein (LDL) for which 
trypanosomes have a receptor (Vansterkenburg et al. 1993), and uptake has been reported as 
being mediated by LDL bound drug being internalised by receptor mediated endocytosis. A 
recent report has, however, reported a non-LDL receptor mediated uptake component in 
trypanosomes (Pal et al. 2002). A mode of action has not been deduced, but seems likely to be 
related to its highly charged state mediating electrostatic interactions with target molecules.
Pentamidine (Figure 1.4), an aromatic diamidine, has been used to treat early stage T. b. 
gambiense infections for over fifty years (Sands et al. 1985). The drug is concentrated to 
millimolar levels within the trypanosomes due to its accumulation through active transport 
(Carter et al. 1995). Pentamidine is taken up through the P2, LAPTl and HAPTl transporters
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(see later). As a polycation, pentamidine interacts with anionic molecules within the 
trypanosome, including DNA (Wang 1995), Other targets have been suggested, but none 
confirmed.
Treatment of trypanosomiasis with pentamidine requires 7 daily intramuscular or intravenous 
injections of 4 mg/kg. The drug can cause serious side effects including hypotension, nausea, 
nephrotoxicity and can result in diabetes.
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Figure 1.4. Drugs used for the treatment of early stage disease.
1.3.3.2 Treatment of Late Stage Disease
Second stage rhodesiense and gambiense disease is most commonly treated with melarsoprol 
(Figure 1.5), a melaminophenyl arsenical that was introduced in 1949. Melarsoprol itself is 
lipophilic and will enter cells via passive diffusion. It is able to dififtise across the blood brain 
barrier (BBB), and clear CNS infections. However, melarsoprol is readily converted to 
melarsen oxide (Keiser & Burri 2000), which is less able to cross the BBB. Melarsoprol and 
melarsen oxide are also accumulated in the trypanosome cell by the P2 purine transporter, the
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loss of function of which has been associated with resistance to arsenical and diamidine drugs 
(see later).
Several modes of action have been suggested for melarsoprol, including inhibition of enzymes 
of glycolysis (Denise et al. 1999; Van Schaftingen et al. 1987) and interactions with low 
molecular weight thiols (Fairlamb et al. 1989; Fairlamb et al. 1992a). However, rapid lysis of 
trypanosomes has been shown to occur before either of these interactions have occurred to 
levels likely to elicit a toxic effect on the cells (FaMamb et al. 1992a; Van Schaftingen et al. 
1987).
As a trivalent organic arsenical melarsoprol is toxic, requiring hospitalisation for treatment 
and causing many, often severe, side effects. The most severe reaction to treatment is a 
reactive encephalopathy occurring in up to 10 % of patients, which can lead to death in up to 
5 % of those treated.
In 1990 Eflomithine (difluoromethylomithine, DFMO, Figure 1.5), was licensed for use. This 
compound is very successfirl in treating both early and late stage T. b, gambiense with very 
few side effects, although T. b. rhodesiense cells have an innate resistance to the trypanotoxic 
effects of the compound. DFMO is the only trypanotoxic compound for which a mechanism of 
action is known. It is an inhibitor of ornithine decarboxylase (GDC), and as such was 
developed for the treatment of cancer, but not carried forward into therapeutic use (Barrett & 
Barrett 2000). Its selective toxicity for the parasite stems from the low rate of turnover of 
GDC in T, b. gambiense as compared to that in mammalian cells (Phillips et al. 1987). The 
effect of DFMO on trypanosomes is cytostatic in nature, requiring an active host immune 
system to clear infections (Bitonti et al. 1986b). Treated cells appear to be more like the short, 
stumpy forms in the bloodstream and are non-dividing and incapable of changing their VSG 
coat.
The activity of DFMO against trypanosomes may be due to a number of factors. The decrease 
in levels of putrescine and spermidine will cause a disruption of many metabolic processes, 
and in particular a decrease in tiypanothione levels and an increase in decarboxylated
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s-adenosylmethionine may contribute. A decrease in the levels of trypanothione in the cells 
would leave them vulnerable to oxidative damage (Fairlamb et al. 1987).
DFMO is reported to enter the cell by passive diffusion (Bitonti et al. 1986a), although one 
report notes the presence of a saturable transport process (Phillips & Wang 1987). The 
treatment regimen of 4 times 100 mg/kg doses, daily for 14 days requires a great deal of the 
compound, which is costly to produce and administer, requiring hospitalisation. Moreover the 
continued production of DFMO is not secured which contributes to the unsatisfactory status of 
this agent as a trypanocide.
COO-
NH3 +
CHFj
a-difluoromethylomitihine (DFMO) 
NH2 S—\
Melarsoprol
Figure 1.5. Drugs used for the treatment of late stage disease.
1.4 Drug Resistance
All of the above compounds have problems in their administration or toxicity to patients. 
Their availability and stability is an issue in affected areas where health care is minimal, if 
present at all. In addition, reports of treatment Allures with these drugs, many of which have 
now been used for over fifty years, are emerging in the field.
In a gambiensian disease focus in Uganda, 30 % of patients treated with melarsoprol relapsed 
within two years of treatment (Legros et al. 1999). In an Angolan focus, 25 % of patients were
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seen to relapse within 30 days (Stanghellini & Josenando 2001), and reports of 16 -  21 % 
relapse rates have been reported in Angola (Brun et al. 2001).
Among the most common reasons for relapses from drug therapy are poor dosing regimens, 
differing drug pharmacokinetics between patients {e.g. inability to cross the BBB in sufficient 
quantities), or factors presented by the parasites themselves leading to an increased tolerance 
to dmgs. That all late stage treatment is administered in hospitals, under the supervision of 
trained medical staff, makes it unlikely that poor treatment regimens are involved in relapses. 
Relapse caused by a decreased ability for drug to cross the BBB in some patients is likewise 
seen as unlikely. A study undertaken in an area of high relapse rates in Uganda has shown that 
the levels of melarsoprol available in the CNS of patients recovering after a single treatment, 
and those that have relapsed, reach the same levels. Consequently, relapse is most likely to 
result from changes within the parasite itself leading to an innate tolerance, or resistance to 
tiypanocides. However, it has been difficult to show significant differences in susceptibility of 
parasites isolated from cured and relapse patients (Brun et al. 2001).
Resistance to the first stage treatments, suramin and pentamidine, is not considered to be a 
serious risk at present. Moreover, any reported treatment failures could be due to the 
misdiagnosis of early-late stage infections as early stage infection, and the subsequent 
reinvasion of trypanosomes from the CNS.
The innate resistance shown by T. h. rhodesiense to the late stage compound, eflomithine, 
which is effective against T. b. gambiense^ has been demonstrated to be due to a difference in 
the rates of turnover of its target, ornithine decarboxylase. Just as the lack of toxicity to 
mammalian cells is due to the rapid turnover of mammalian ODC as compared to that of T. b. 
gambiense, T b. rhodesiense ODC has a higher specific activity and a shorter half life (4.3 h) 
than its gambiensian equivalent (>18 h) (Iten et al. 1997).
Resistance to melarsoprol has been readily induced in laboratory strains, and is now being 
seen in the field. The development of resistance to arsenicals, and cross-resistance to 
diamidines, has been proposed to be mediated by the loss of function of the adenosine 
transporter, P2 (Carter & Fairlamb 1993).
14
Chapter I. Introduction.
By screening a range of nitrogenous biochemicals, Carter and Fairlamb demonstrated that the 
lysis of trypanosomes by melarsen oxide was delayed by the addition of adenosine to lysis 
assay buffer. They also demonstrated that the transport of [^H] adenosine into trypanosomes 
could be inhibited by melarsen oxide, suggesting that an adenosine transporter was involved in 
the uptake of this dmg into trypanosomes. Further studies showed there are two distinct 
adenosine transport systems, one inhibitable by inosine, accounting for around 70 % of 
adenosine uptake, and one inhibitable by adenine, melarsoprol and melarsen oxide, accounting 
for approximately 30 % of adenosine uptake. The two transport systems were labelled PI and 
P2 respectively, and a melarsen resistant hne, T. b. brucei 427 cRU15 (Fairlamb et al. 1992b), 
was shown to have a reduced PI activity and to have lost P2 activity altogether (Carter & 
Fairlamb 1993).
This same melarsen resistant strain was also resistant to some diamidines. Pentamidine 
blocked the lytic action of melarsen oxide as well as inhibiting the uptake of adenosine, 
showing an interaction with P2. However, adenosine failed to block the uptake of 
radiolabelled pentamidine to the expected degree. A 100 fold excess of adenosine could only 
block pentamidine uptake by 85 %, indicating that additional transporters for pentamidine 
could play a role in its uptake (Carter et al. 1995). The presence of additional transporters for 
pentamidine has since been confirmed with a fiirther two transporters identified in T, b. brucei 
(de Koning 2001b).
1.4.1 The Molecular Basis of Drug Resistance
With the emergence of drug resistant and cross-resistant strains, the search for the molecular 
basis of resistance has become more important. The gene encoding the P2 nucleoside 
transporter, TbATl, was described by Maser fi'om a Trypanosoma brucei brucei library 
transfected into a strain of yeast defective in purine biosynthesis (Maser et al. 1999). The 
transfected yeast cell line, which does not normally transport adenosine, was then plated out 
onto a medium containing adenosine as the sole source of purine. In this way the transfected 
cells, which contained TbATl encoding the T brucei P2 transporter, were isolated.
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TbATl encodes a 463 amino acid hydrophobic polypeptide, with 11 predicted transmembrane 
a-helices, a cytosolic amino terminus and an extracellular carboxy terminus and a large 
cytosolic loop between transmembrane domains 6 and 7 (Figure 1.6). The P2 transporter 
expressed in yeast was inhibitable by adenine and made transfected cells more susceptible to 
arsenicals than wild type cells. Transport studies showed, however, that pentamidine was 
unable to block adenosine uptake in the cells, which could be due to incorrect processing of 
the transporter protein in yeast cells.
The P2 transporters from an arsenical resistant strain, STIB 777R and the arsenical sensitive 
parent strain, STIB 777S, were then cloned and expressed in yeast. The sequence from the 
sensitive strain was found to be identical to the sequence already described, but the sequence 
of the resistant strain had 10 nucleotide changes that translated into 6 changes at the amino 
acid level (Figure 1.6). The resistant clone expressed in yeast failed to increase sensitivity to 
arsenicals, and did not induce uptake of adenosine either, suggesting that the mutation in STEB 
777R has produced a non-functional P2 transporter, as opposed to one that has altered 
substrate specificity.
COOH
Cytoplasm
Figure 1.6 Predicted structure of TbATl.
(R. Burchmore) Amino acid sequence changes in STIB 777R are highlighted in red. In sequence these are L71V, 
A 178T, G181E, D239G , N 286S and L380P.
Other arsenical and diamidine resistant cell lines have been shown to have alterations in their 
P2 transporter. A diamidine resistant strain of T. equiperdum^ derived by sub-curative dosing 
in vivo, has been found to have a much reduced P2-like adenosine transport component.
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Because of the residual P2-like activity, it seemed likely that the change in P2 activity was due 
to a loss in affinity for the drugs as substrates, rather than a loss in P2 function (Barrett et al. 
1995).
T. b. brucei 247 mr and T. b. gambiense 386 mr are arsenical resistant cell lines, both of which 
were derived in vivo by serial passage in increasing sub-curative doses of cymelarsan (Scott et 
al. 1996). T. b. brucei 247 mr has recently been shown to lack an open reading frame for 
TbATl, and T. b. gambiense 386 mr has an intact open reading frame, but lacks a detectable 
TbATl transcript (R. Burchmore, unpublished data).
A T. evansi cell line that was selected for resistance to cymelarsan, and was also resistant to 
berenil treatment had lost adenosine transport via P2. The wild type parent strain is reported, 
however, to have three adenosine transporters, unlike other studies which report only two 
(Ross & Bams 1996).
A study of CSF infections of patients from a focus in north-western Uganda has also identified 
mutations in TbATl in trypanosomal isolates from both newly infected cases and relapse 
patients (Matovu et al. 2001b). Their findings showed that all of the isolates that showed a 
mutant genotype by restriction enzyme fragment length polymorphism (RFLP) and single 
stranded conformational polymorphism (SSCP) had the same mutations in TbATl. Out of the 
9 point mutations present in these extracts, 8 are identical to those found in the laboratory 
derived drug resistant STIB 777R strain. Furthermore, two more isolates, STIB 871, a drug 
resistant T h. rhodesiense isolate from south-eastern Uganda, and K003, a T. b. gambiense 
stock isolated from a melarsoprol relapse patient in northern Angola also showed identical 
point mutations in TbATl, which were the same as those in the CSF isolates (Figure 1.7). A 
representative sample of CSF isolates that showed wild type RFLP and SSCP patterns were 
sequenced and showed wild type TbATl sequence.
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Changes in amino 
acid sequence
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Changes in C21T T144C C211G C471T G532A A716G A857G T1I39G
nucleotide sequence C501T G542A
STIB 777R X X X X X X X X X X
CSF Isolates X X X X X X X X X
STIB 871 X X X X X X X X X
K003 X X X X X X X X X
Figure 1.7 Mutations in TbATl are highly conserved in drug resistant cell lines and field 
isolates.
From Matovu, E., 2001. The blue bar represents the TbATl ORF. The mutations C 21T, T144C, C 21IG , C471T, 
G 532A , G 542A , A716G and A857G are all present in STIB 777R, CSF isolates from Uganda, STIB 871 and 
K003.
One isolate, KOOl, a T b. gambiense stock isolated ftom a melarsoprol relapse patient in 
northern Angola lacked TbATl altogether, creating a ‘natural knockout’. A constructed 
ATbatl (P2 knock out) cell line (E. Matovu, unpublished data) does not have any P2 transport 
activity, and shows some resistance to melarsoprol (two fold increase in I C 5 0 ) .  Many isolates 
fiom relapse patients, however, showed no difference in TbATl indicating that the situation in 
the field regarding resistance and P2 transport is very complicated, and that other routes to 
resistance exist.
1.4.2 A Possible Link with Resistance to Veterinary Trvpanocidcs
Many wild and domestic animals suffer tfom trypanosomiases, caused by various 
trypanosome species, most notably T congolense and T vivax, but also T. b. brucei, 
T. equiperdum and T evansi. Infection in domestic cattle causes a disease known as Nagana, 
which can cause a 20 % decrease in calving, a 25 % decrease in milk production as well as an 
estimated 3 million livestock deaths per year (Seed 2000). Outbreaks of Nagana and HAT 
restrict land use and inhibit agricultural development of otherwise agreeable rural areas.
There is also evidence that domestic cattle can act as a reservoir host for T. b. rhodesiense, 
which causes the acute form of HAT. The first report of a human infective trypanosome
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species isolated from an animal is that of a strain of T. b. rhodesiense isolated from a 
bushbuck (Heisch et al. 1958). More recently DNA and isoenzyme analysis of isolates from 
cattle have shown that up to 23 % of infected cattle in an epidemic area contain human 
infective trypanosomes as indicated by the above techniques (Hide 1999).
In a recent publication it was reported that a programme to restock an area in Uganda with 
cattle from outwith the surrounding area has directly resulted in an outbreak of T. b. 
rhodesiense sleeping sickness (Fevre et al. 2001). The authors found that 54 % of cattle 
imported in a 4 year period preceding the outbreak originated from sleeping sickness endemic 
areas. They also found that there was a significant correlation between the distance from the 
main market area and the spread of the epidemic. It was unlikely that human carriers of the 
parasite were the cause of the outbreaks as none of the human cases presented reported 
travelling from or into the area. This all suggests that the cattle carried human infective 
parasites into the area and the native Glossina spp, Glossina juscipes fuscipes, is responsible 
for their spread into the human population.
The above authors conclude with the suggestion that the testing of animals and the treatment 
of all cattle in the programme with one curative dose of trypanocide could curtail the 
dispersion of HAT into new areas. While on the surface this appears to be an exceptionally 
good idea, further scmtiny reveals it could be a risky strategy depending on the nature of the 
trypanocidal agent used and the competence of its application.
The growth of resistance to a drug m a field situation can be associated with one or more 
factors. Among the most important of these are the compound’s widespread use, prophylactic 
use and self-administration. These can all lead to the administration of inappropriate doses, 
and expose the infecting organism to sub-curative doses of drug that can, over time, lead to 
resistance.
None of these factors are likely to occur frequently enough through melarsoprol treatment to 
result in resistance. Although HAT is a very significant health problem, it is still a relatively 
uncommon disease when compared to, for instance, malaria, for which there is widespread 
drug resistance. This means that melarsoprol treatment is probably not widespread enough to
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lead to resistance. The drug is not used as a prophylactic and requires hospitalisation for 
treatment, so the administration of sub-cumtive doses is rare.
The treatment of cattle with berenil to treat Nagana, however, does fit all the above criteria to 
raise resistance to berenil. Berenil is administered by farmers and is often used as a 
prophylactic. The compound should be purchased from pharmacies, but is widely available on 
the black market. A survey of these black market products showed that they could contain 
between 0 and 90 % diminazene aceturate, the active component of berenil. More worryingly, 
legally obtained products were also found to contain hugely varying amounts of diminazene 
aceturate (Tetty et al. 2002), Add to this the fact tliat farmers may underestimate the weight of 
their cattle, and may not treat an entire herd, but only those that appear ill, and the likelihood 
of a trypanosome encountering a sub-curative dose of berenil becomes very high.
Both berenil and melarsoprol, or their active metabolites, exploit the trypanosome specific P2 
purine transporter to enter the parasite cells, and the development of drug resistance is closely 
related to the loss of this transporter (Barrett & Fairlamb 1999). It is relatively easy to select 
for cross-resistance between berenil and in vitro and in vivo, and cross-resistance has been 
observed in the field. Human infective trypanosomes infecting cattle could potentially develop 
a resistance to berenil and carry cross-resistance to melarsoprol into humans.
The importance of this pathway to melarsoprol resistance in T. b. gambiense infections is 
uncertain. This parasite has been reported to exist in domestic animals, but only to a very 
limited extent. It is in fact unlikely that this reservoir could play any role in the epidemiology 
of the disease (Noireau et al. 1986). In T. b. rhodesiense, however, upwards of 20 % of 
domestic cattle can be carrying human infective pathogens which could develop resistance to 
berenil treatment leading to cross resistance to melarsoprol.
1.5 Nutrient Transporters Implicated in Drug Uptake and Resistance
Several classes of nutrient tranporters have been identified in T. brucei. Among these are the 
purine, glucose and amino acid transporters, and the ongoing trypanosome genome project is 
likely to identify even more. As around 5-10 % of the genomes of most organisms encode
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membrane transporters, it is probable that the T. brucei genome carries around 400 transporter 
genes (Borst & Fairlamb 1998).
At least 3 trypanosome transporters have been identified as being able to earry drugs into the 
trypanosomes, and their activity may be the reason for the selectivity of these drugs for 
trypanosomal cells as opposed to mammalian cells.
1.5.1 Purine Transporters
Trypanosomes are unable to synthesise the purine ring de novo, relying upon their external 
environment for a supply (Hammond & Gutteridge 1984). To facilitate this they have 
developed an array of salvage enzymes and purine transporters, among which are the PI and 
P2 nucleoside transporters (Carter & Fairlamb 1993). Targeting trypanosome purine 
transporters or salvage enzymes in the design of new trypanocidal compounds is relatively 
futile due to the large amount of redundancy built into the system. Whilst blocking purine 
uptake would doubtless be detrimental to the trypanosomes, to do so would require a cocktail 
of inhibitors to be administered to the patient.
hi comparison, mammalian cells are able to make the purine ring and therefore have less need 
to salvage purines fi'om the environment (Griffith & Jarvis 1996). Most mammalian 
nucleoside and nucleobase transporters recognise a wide variety of substrates, including both 
purines and pyrimidines, and have a lower affinity for their substrates than the trypanosome 
transporters (de Koning & Jarvis 1999).
The P2 transporter is of particular interest being able to facilitate the internalisation of a wide 
range of trypanocidal drugs. Both the PI and P2 transporters have been extensively 
characterised, and their recognition motife, the part of the substrate molecule that the 
transporter recognises and binds to prior to internalisation, have been established.
1.5.1.1 The PI Transporter
The PI transporter is a very high affinity and high capacity transporter for adenosine 
(Km = 0.38 +/- 0.1 pM, Vmax = 2.8 +/- 0.4 pmol /10^ cells / s) and inosine, and shows a high
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affinity for all natural purine nucleosides (de Koning & Jarvis 1999). As for other 
characterised purine transporters (de Koning & Jarvis 1997), PI has been shown to be driven 
by protonmotive force (de Koning et al. 1998). The recognition motif for PI is illustrated in 
Figure 1.8.
The ribose moiety is essential for binding to PI. The hydroxyl groups at positions 3 and 5 are 
essential, but the hydroxyl group at position 2 does not appear to be involved in binding. The 
nitrogens at positions 3 and 7 are also required for high affinity binding. Although C2 is not 
directly involved in binding to the transporter, substitutions at C2 can reduce the negative 
charge at N3, slightly reducing affinity. The same happens at N7 with substitutions at C8 and 
N9 (de Koning & Jarvis 1999).
HO
OH OH
Adenosine
Figure 1.8 Adenosine, highlighting the PI recognition motif.
The primary recognition m otif is shown in red.
1.5.1.2 The P2 Transporter
The P2 transporter has a high affinity for 6-amino purines, its natural substrates being 
adenosine (with a Km o f0.92 +/- 0.06 pM ,and a Vmax of 1.12 +/- 0.08 pmol /10^ cells / s) and 
adenine (de Koning & Jarvis 1999). It has not been shown how transport by P2 is mediated, 
but it is likely that it is also protonmotive force driven. The recognition motif for P2 is 
illustrated in Figure 1.9.
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The selectivity of P2 for purines suggests that the purine ring is important in the binding motif, 
and the most important groups involved in substrate recognition are the amine group at 
position 6 and the nitrogen at position 1 of the purine ring. These two groups together are seen 
as the primary P2 recognition motif: H2N-C(Ri)=N-R2 . The aromaticity of the purine ring 
may also contribute to binding through jr-stacking interactions, and substitutions at C2 reduce 
affinity, possibly by reducing the electron density at Nl. N3 and N7 are not involved in 
binding.
The ribose moiety is not important for binding to P2. In feet adenine, which lacks the ribose 
group, has a slightly higher affinity for P2 than adenosine. Substitutions at N9 do affect 
binding, but only to a very small extent (de Koning & Jarvis 1999).
Primary 
recognition 
m otif NH
HO
Ribose moiety not 
involved in
OH OH binding 
Adenosine
Figure 1.9 Adenosine, highlighting the P2 recognition motif.
The primary recognition m otif is shown in red.
1.5.1.3 Exploitation of the P2 Transporter for Drug Uptake
One approach to the design of new trypanocides, which is used in this study, is that of 
targeting compounds to the parasite through a specific transporter with a unique recognition 
motif. P2 is a good candidate as a ‘gateway’ for drug targeting in this way as substrates with 
the P2 binding motif, H2N-C(Ri)=N-R2, show a high affinity to P2 and a low affinity for 
mammalian transporters. The P2 transporter also concentrates substrates within the cell, and 
there is a low abundance of natural substrate in the bloodstream that would compete for 
binding sites with any potential drugs. Toxic moieties linked to the P2 recognition motif
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would hopeMly be less toxic to mammals as the target cells would take up the majority of 
drugs. Also, due to the concentrative nature of P2, less drug would need to be delivered into 
the mammal, reducing the effective dose and the risk of toxicity even fiirther. This approach 
has already been used as a mode of delivery for polyamine analogues (Tye et al. 1998), nitric 
oxide releasing compounds (Soulere et al. 2000), and organotin compounds (Susperregui et al. 
1999).
P2 has been linked with drug resistance in the lab, generally through the loss of function of the 
transporter. If this situation were to be mirrored in the field there would be a significant risk 
that compounds designed in this way, to be internalised through the P2 transporter, would 
rapidly lose their usefiilness due to resistance. The situation regarding P2 and dmg resistance 
in field situations is not clear however. Although there are scattered reports of a connection 
between P2 status and drug resistance, there are also reports, ofl;en in the same studies, of drug 
resistance that appears to be unrelated to P2 transport (Brun et al. 2001). Any new compound 
is also likely to be administered by trained staff under controlled conditions, lessening the 
likelihood of fiirther resistance developing.
1.5.2 Pentamidine Transport
Pentamidine is able to cross the trypanosome cell membrane using the P2 transporter. Two 
additional transporters for pentamidine have also been identified (de Koning 2001b). These 
are the high affinity, low capacity transporter (HAPTl) and the low affinity, high capacity 
transporter (L APT 1 ).
The high affinity transporter has a Km value of 0.036 +/- 0.006 pM, and a Vmax of 0.0044 +/- 
0.0004 pmol / 10  ^ cells / s. Although HAPTl has a very high affinity for pentamidine, the 
transporter is quickly saturated and uptake via HAPTl is only likely to be significant at very 
low extracellular concentrations (< 0.01 pM). The low affinity transporter has a Km value of
56.2 +/- 8.3 pM, and a Vmax of 0.85 +/- 0.15 pmol / 10  ^cells / s. This transporter is able to 
carry more pentamidine across the cell membrane but, due to its very low affinity for 
pentamidine, only becomes of significance at higher concentrations (>50 pM). The P2
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transporter fells between these two in terms of Km (0.26 +/- 0.03 |JlM ), and Vmax (0.068 +/- 
0.007 pmol /10^ cells / s), and at any physiologically significant concentration of pentamidine 
is responsible for at least 50 % of transport into the trypanosome cell (Figure 1.10).
■ HAPT1
■ LAPTl
■ P2
■ Total
Max. plasma conc. in patients
1 0 '
[PentamidineI (M)
Figure 1.10 Pentamidine uptake rates bv the various transporters in T. b. brucei bloodstream 
forms.
Reproduced from Bray P. G., 2003. Uptake rates are plotted as a function o f  the extracellular pentamidine 
concentration from V = (V„ax x L)/(L + K„) in which L is the ligand concentration. Plasma concentrations in 
patients treated with the standard 4 mg/kg dosing have been determined at 0.5 -  2.5 pM (Waalkes & DeVita 
1970).
1.6 Potential Drug Targets
As described previously, the current drugs available for the treatment of trypanosomiasis are 
mostly over fifty years old, some are toxic and there is increasing resistance. The development 
of new chemotherapeutic compounds is of great importance, and the search focuses on 
differences between the biochemistry and metabolism of the parasites and their mammalian 
hosts that can be exploited as drug targets. The trypanosome genome project has aided in the 
identification of potential targets through comparative genetics, and lead compounds have 
been designed as inhibitors of trypanosome specific targets. Targets have been further
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validated in gene knockout experiments (Clayton 1999; Kelly et al. 1995) and, more recently, 
using RNAi methods (LaCount & Donelson 2001).
1.6.1 Purine Transport and Metabolism
Purines are essential to tiypanosomes, their uptake and metabolism is different in many ways 
from mammalian systems (Marr 1991), and blocking purine transporters or salvage enzymes 
could be sufficient to stop parasite growth. The parasite however, has many purine 
transporters, recognising different substrates, which can then be interconverted by different 
salvage enzymes. Effective blocking of purine metabolism would require the administration of 
a large mixture of inhibitors to patients, which is impractical. As previously described, 
however, many nutrient transporters, including the purine nucleoside and nucleobase 
transporters, could act as gateways for the transport of trypanocides specifically into 
trypanosomes.
1.6.2 Polvamine Metabolism
Polyamines in Afifican trypanosomes include putrescine and spermidine, which have 2 or 3 
amine groups respectively. A glutathione-spermidine conjugate called trypanothione is also 
unique to this group of organisms. Polyamine metabolism has been validated as a target in 
trypanosomes by the action of DFMO on ornithine decarboxlyase, the first enzyme in the 
polyamine synthesis pathway (Giffin et al. 1986; Wang 1995).
Further studies on the polyamine pathway have focused on inhibiting the action of S~ 
adenosylmethionine decarboxylase, a crucial enzyme in the synthesis of putrescine and 
spermidine. The compounds CGP 40215, a diamidine produced by Ciba-Geigy as part of then 
anticancer programme, and methylgloxyl bis(guanylhydrazone) have been screened for their 
therapeutic effects. Their therapeutic activity was found to be limited to early stage infections, 
and the compounds were subsequently abandoned as potential drugs (Keiser et al. 2001).
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1.6.3 Trypanothione Metabolism and Oxidative Stress
Trypanosomes contain trypanothione, a glutathione-spermidine conjugate that ftinctionally 
replaces glutathione found in most cell types. The parasite specific enzyme, trypanothione 
reductase, is critical in maintaining reduced trypanothione to maintain an intracellular 
reducing environment (Fairlamb & Le Quesne 1997; Kreiger et al. 2000). The absence of 
trypanothione reductase from the cell results in a loss of virulence and leaves trypanosomes 
vulnerable to attack by oxidative stress (Kreiger et al. 2000). The inhibition of trypanothione 
reductase or blocking trypanothione production are considered as targets for drug development 
(Schmidt & Krauth-Siegel 2002).
Trypanosomes also lack the enzymes catalase and glutathione peroxidase, which m most 
eukaryotes detoxify hydrogen peroxide. The nitrofuran, Nifrirtimox, has activity against T. 
cruzi and has also been suggested for use in cases of melarsoprol refractory T. brucei 
infections (Pepin et al. 1992) Its activity is mainly attributed to the reduction of the nitro group 
to form the nitro anion free radical (NO2 "). This reactive species may then exert its toxicity by 
interacting with parasite macromolecules, or by reacting with oxygen to produce reduced 
oxygen by-products such as 0 2 ~ or H2O2 that could cause oxidative stress within the cell.
1.6.4 Other Potential Drug Targets
1.6.4.1 Glvcolvsis
Tiypanosomes rely upon glucose metabolism for all their energy production. Many enzymes 
of glycolysis in trypanosomes are functionally and stmcturally different from mammalian 
enzymes, partly due to the fact that the first seven enzymes of the pathway reside within 
unusual peroxisome-type organelles called glycosomes (Michels et al. 2000.). Inhibitors of the 
glycolytic enzymes are being pursued (Verlinde et al. 2001).
1.6.4.2 The Pentose Phosphate Pathway
In trypanosomes, enzymes of the pentose phosphate pathway (Barrett 1997; Cronin et al. 
1989), as well as other pathways, are related to cyanobacteria rather than to those of
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eukaryotes (Haimaert et al. 2003). The third enzyme of the pentose phosphate pathway, 6- 
phosphogluconate dehydrogenase, is essential to trypanosomes, and selective inhibitors have 
been designed to exploit the structural differences of the trypanosome enzyme relative to its 
mammalian counterpart (Barrett & Gilbert 2002).
1.6.4.3 Kinetoplast/RNA Editing
The kinetoplast is the unusual mitochondrial DNA network that exists in Trypanosomes 
(section 1.2.3). It has a very complex topology maintained by topoisomerases, which are 
responsible for maintaining this topology throughout replication, transcription and 
recombination. These topoisomerases may provide targets for drug design (Wang 1994).
RNA editing is a process unique to trypanosomes. In this respect, components of this process 
may provide a promising target for drug development (Stuart et al. 1997).
1.6.4.4 Lipid and Sterol Metabolism
Ergosterol is the major sterol in trypanosomatids, whereas in mammals, the predominant sterol 
is cholesterol. The enzymes involved in sterol biosynthesis in trypanosomes vary accordingly, 
and act as potential targets. Inhibitors of sterol methyl transferase inhibit the growth of 
the related trypanosomatids, Crithidia fasciculata (Rahman & Pascal 1990) and T. cruzi 
(Urbina et al. 1996).
1.7 The Role of the P2 Purine Transporter in Drug Uptake and Resistance
Any potential drug designed to affect any of the parasite specific targets described above will 
have to cross the trypanosome cell membrane. A lipophilic compound that can cross any cell 
membrane, including that of the mammalian host, could achieve this. However, although toxic 
or inhibitory compounds can be designed to a target that is specific to the parasite cell, a 
compound that has access to any cell increases the risk of toxicity to the host cell.
Another strategy for crossing the trypanosome cell membrane is to exploit the action of a 
parasite membrane transporter with a high affinity for a particular substrate, and a recognition
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motif for that substrate unlike any in mammalian cells. By using this transporter as a gateway, 
it should be possible to target compounds to the parasite cell specifically. The P2 aminopurine 
transporter fiilfils this requirement as a ‘gateway’ for parasite specific uptake in that it requires 
a recognition motif which appears to be very unusual and for which it has a high affinity 
(Hasne & Barrett 2000). With this objective in mind, compounds were designed and tested for 
their ability to interact with the P2 transporter and their overall toxicity to trypanosomes in 
vitro and, where appropriate, in vivo.
The P2 transporter has other properties that lend themselves to its being used as a gateway. 
The natural substrates for this transporter, adenine and adenosine, are found at very low 
concentrations in the bloodstream. This means they will offer very little competition for the 
transporter. Also, the P2 transporter is likely to be driven by a protonmotive force, and 
actively accumulates substrate against the concentration gradient. If it were able to do this 
with a trypanocide, less compound would have to be administered to the patient and yet 
achieve high concentrations within the parasite, reducing the likelihood of toxic side effects.
In spite of its potential utility as a novel gateway, the loss of the P2 transporter has been linked 
with drug resistance in laboratory strains, and has been reported to be involved in some cases 
of drug resistance in the field. Because of fears about the development of drug resistance, this 
study also seeks to further clarify the molecular basis of drug resistance and the role of the P2 
transporter. To this end, the molecular basis for the development of drug resistance in a 21 
equiperdum strain that has been reported to have a P2 transport component with a greatly 
reduced affinity for adenosine has been investigated.
A test for drug resistance through the loss of an active P2 transporter is also pursued. Tests 
related to P2 transport have been suggested previously, however, these are unsuitable for use 
in the field, where they would be most useful, to both clinicians and scientists investigating the 
phenomenon of drug resistance in Afiican trypanosomes.
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2.1 Trypanosome Cell Lines
2.1.1 TrvDanosoma brucei brucei 427
T. b. brucei strain EATRO (East African Trypanosomiasis Research Organisation) 427 was 
used routinely for uptake assays. The strain is reported to have been isolated from a sheep in 
Uganda (Cuimingham & Vickerman 1962) and is extensively used for experimental purposes 
as very high parasitaemias can be achieved in experimental animals. Most biochemical 
analyses in T. brucei have been done using this strain. These stocks were supplied by Dr. M. 
P. Barrett, University of Glasgow.
2.1.2 T. b. brucei 427. MiTat 1.2 (BS221) and ATbatl mutant clone
The ATbatl (P2) null mutant clone was constructed by sequential replacement of TbATl with 
the neomycin and puromycin resistance markers in T. b. brucei 427, MiTat 1.2 (BS221). The 
knockout cell line was 4-fold less sensitive to melarsoprol, melarsen oxide and 18.6-fold less 
sensitive to diminazene aceturate (Enock Matovu, unpublished data). These stocks were 
originally supplied by Enock Matovu and are held at the University of Glasgow.
2.1.3 T. b. brucei 247 and 247 mr
STIB (Swiss Tropical Institute, Basel) 247 was originally isolated from a hartebeest in 1971 in 
the Serengeti National Park, Tanzania (Jenni et al. 1986). The cymelarsan resistant 247 mr cell 
line was derived by serial passage in mice treated with subcurative doses of cymelarsan. The 
resulting clone was found to be 130-fold less sensitive to cymelarsan and 16-fold less sensitive 
to berenil in vivo (Scott et al. 1996). These stocks were originally supplied by Dr. C. M. R. 
Turner, University of Glasgow. The T, b. brucei 247 mr cell line has been shown to lack the 
TbATl open reading frame, resulting in a ‘natural knockout’ of P2 transport frmction (R. 
Burchmore, unpublished data).
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2.1.4 T. b, sambiense 386 and 386 mr
STIB 386 was originally isolated from a man in Daloa in the Ivory Coast. The cymelarsan 
resistant 386 mr cell line was also derived by serial passage in mice treated with subcurative 
doses of cymelarsan. T. b. gambiense strain 386 mr is 20-fold less sensitive to cymelarsan in 
vivo (Scott et al. 1996). These stocks were originally supplied by Dr. C. M. R. Turner, 
University of Glasgow. 386 mr carries a frill open reading frame for TbATl, but lacks any 
detectable transcript of that gene (R. Burchmore, unpublished data).
2.1.5 T. eauioerdum BoTat 1 P and PBR
T equiperdum BoTat 1 (Bordeaux trypanozoon antigenic type 1) P originated from a stock 
held at the Pasteur Institute, Paris. The berenil resistant line, T equiperdum PBR was derived 
from the parent cell line by serial passage through mice treated with sub-curative doses of 
berenil (Zhang et al. 1993). The resistant cell line is 35.6-fold less sensitive to berenil and 4- 
fold less sensitive to cymelarsan in vitro. In vivo, the resistant cell line is insensitive to berenil 
up to the maximum tolerated dose in Swiss mice, and 4-fold less sensitive to cymelarsan. 
These stocks were originally supplied by Dr. Theo Baltz, Université de Bordeaux, and are held 
at the University of Glasgow.
2.2 Growth and Maintenance of Trvpanosome Stocks
2.2.1 Bloodstream Form Trvpanosomes
2.2. In vivo culture
Trypanosomes were stored in capillary tubes, in liquid nitrogen storage facilities, in blood 
containing 10.5% DMSO. Wistar rats or ICR mice (depending on the number of trypanosomes 
required) were infected by intraperitoneal injection of the parasite stabilates. Parasitaemias 
were checked daily by examination of a tail blood smear under phase contrast. Parasitaemia 
was scored using the rapid matching method (Herbert & Lumsden 1976).
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Wlien the parasitaemia reached 1x10® cells/ml the animal was sacrificed using CO2 and the 
blood collected by cardiac puncture in a syringe containing 100 U/ml heparin in CBSS 
(Appendix I),
22.1.2 In vitro culture
Cultures were incubated in sterile culture flasks at 37®C and 5% CO2 in HMI-9 medium 
(Hirumi & Hirumi 1989) containing 20% heat-inactivated foetal calf serum. 5 ml cultures 
were seeded with 200 pi of culture at 2 x 10  ^cells/ml. Cells were allowed to grow for 3 days 
afi;er which they had reached maximum density (approximately 2 x 10  ^ cells/ml) and were 
passaged again in the same way.
2.2.2 In vitro Culture of Procvelic Form Trvpanosomes
Cultures were incubated in sterile culture flasks at 28”C and 5% CO2 in SDM-79 medium 
(Brun & Jenni 1977) containing 10% heat-inactivated foetal calf serum. 5 ml cultures were 
seeded with 200 pi of culture at 10  ^ cells/ml. Cells were allowed to grow for 3 days after 
which they were passaged again in the same way.
2.3 Chemicals
2,5-bis (4-amidinophenyl) furan (DB 75) and 2,5-bis (4-amidinophenyl) 2,3-bis methylfiiran 
(DB 544) were gifts fi'om Dr R. Tidwell, University of North Carolina and Prof. D. Boykin, 
Georgia State University. Polyamine analogues, HIV gpl20 binding mimetics and the 
nitrofuran and nitroimidazole compounds were synthesised in Cardiff at the Welsh School of 
Pharmacy by Burkhard Klenke, Gorka Jimenez-Bueno, C, Boussard and Ian Gilbert. Alamar 
Blue was obtained firom Trek Diagnostic System Ltd. Oligonucleotides were synthesised by 
MWG Biotech. Restriction enzymes and Pfu DNA polymerase were purchased firom Promega. 
Radiolabeled [2,8, -^H] adenosine (35.9 Ci/mmol) was purchased fi*om Perkin Elmer, [ring - 
^H] Diminazene aceturate (83 Ci/mmol) was purchased from Amersham Pharmacia Biotech 
(custom synthesis) and [a^^P] ATP (3000 Ci/mmol) was purchased ft-om NEN Life Science 
products. All other chemicals were of the highest grade available from Sigma.
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2.4 Transport Assays
2.4.1 Separation of Trvpanosomes from Blood
Parasites were separated from blood using a DEAE cellulose column (Lanham & Godfrey 
1970). Whole blood containing the parasites was centrifuged at 1250 x g for 15 minutes. The 
trypanosomes form a layer over the red blood cell pellet, which was removed by pipetting. 
The trypanosome layer was then resuspended in separation buffer, PSG (Appendix I), and 
applied to the DEAE cellulose (DE-52) column, where under standard conditions, the red 
blood cells are negatively charged, and adhere to the cellulose, and the trypanosomes are 
positively charged and can pass through the column to be collected beneath.
Trypanosomes were further prepared for use in uptake assays by washing three times in ice 
cold CBSS to remove soluble blood components. After the final wash, cells were resuspended 
to 2 X 10  ^cells/ml in CBSS in preparation for the assay.
2.4.2 Uptake Assays
Uptake assays were based on a protocol described by Carter and Fairlamb, 1993 (Carter & 
Fairlamb 1993).
2.4.2.1 Prelhninarv Uptake Assav -  Establishing the Required Range
The approximate concentration that inhibited 50% of radiolabeled adenosine uptake in 
trypanosomes (IC50) was established in order to select the range of concentrations of inhibitor 
to use in the full uptake assays.
100 pi of CBSS containing 0.05 pM radiolabeled âdénosiiie and 1 mM mosine (to block 
adenosine uptake via the PI transporter) was layered over 100 pi of oil (1-Bromododecane, 
97%, density 1.04 g/ml). Experiments included four 10-fold dilutions, from 1000 pM, of the 
potential inhibitor added to individual tubes, and a no inhibitor control.
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100 pi of trypanosomes at 2 x 10® cells/ml in CBSS, purified fi'om blood as detailed above, 
were added to the experiment tubes and incubated for 10 s at 25 “C. After incubation the 
reaction tubes were centrifuged at 10,000 x g for 1 minute in a Biofuge pico benchtop 
centrifuge. The cells descended through the oil layer to form a pellet separated firom the excess 
radioactivity in the aqueous phase. The entire reaction tube was flash frozen in liquid nitrogen 
and the oil layer containing the pellet was cut off into a scintillation vial.
2% SDS and 2.5 ml of Ecoscint scintillation fluid was added to the samples and these were left 
overnight to ensure against luminescence quenching. The radioactivity present was measured 
in a Wallac Trilux 1450 Microbeta liquid scintillation counter. The apparent IC50 value for the 
inhibitor was calculated by analysing the data with the IC50 value algorithm of the Grafit 4,0 
software. Each experiment was done in duplicate.
2.4.2.2 Ki Determination Assav
100 pi of CBSS buffer containing 1 mM inosine (to block adenosine uptake via the PI 
transporter) and either 5, 2.5, 1.25, 0.625 or 0.3125 pM radiolabeled adenosine was layered 
over 100 pi of oil (1-Bromododecane, 97%). Three concentrations of inhibitor compound, 
spanning the calculated IC50 value and one no inhibitor control, were added to the above tubes 
giving four separate dilution series.
100 pi of trypanosomes at 2 x 10® cells/ml, purified from blood as described above, were 
added to the tubes which were incubated for 10 s at 25”C. The cells were then centriftiged 
through the oil layer to form a pellet separated from the excess radioactivity in the aqueous 
phase. The entire reaction tube was flash frozen in liquid nitrogen and the oil layer containing 
the pellet was cut off into a scintillation vial. The radioactivity present was measured by 
scintillation counter. The apparent Ki value for the inhibitor was calculated using the 
competitive inhibition equation from the Grafit 4.0 software. Each experiment was done in 
duplicate.
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2 A 2 3  Inhibition of Uptake of radiolabeled Diminazene Aceturate and Adenosine bv an 
Excess of Transport Substrates
The uptake of 20 pM Diminazene Aceturate (berenil) and 10 pM adenosine was measured 
over 10 minutes at 25 °C.
1 mM concentrations of adenine, inosine and hypoxanthine, either singly or together, were 
combined in 100 pi of CBSS containing radiolabeled substrate. 100 pi of trypanosomes at 2 x 
10® cells/ml, purified jfrom blood as described above, were added to the tubes, which were then 
incubated for either 30,60,120, 300 or 600 s at 25^C. The cells were then spun through the oil 
layer to form a pellet separated from the excess radioactivity in the aqueous phase. The entire 
reaction tube was flash firozen in liquid nitrogen and the pellet cut off into a scintillation vial. 
The radioactivity present was measured by scintillation counter. Each experiment was 
conducted in triplicate.
2.5 Trvpanotoxicity
2.5.1 In vitro Toxicity Assav lAlamar Blue Assay)
The Alamar Blue Assay (Raz et al. 1997) was used to assess toxicity in vitro. Doubling serial 
dilutions of test compound were set out in a 96 well plate in duplicate, in a volume of 100 pi 
HMI-9. 100 pi of trypanosomes at 2 x 10^  cells/ml where added to each well. After 48 h 
incubation at 37^C and 5% CO2 , 10% Alamar Blue (20 pi) was added to each well and the 
plates incubated for a further 24 h. Unspecified enzymes in live cells reduce the Alamar Blue 
to a pink colour. The concomitant change in absorption at 600 nm can be measured 
spectrophotometrically, or fluorometric measurements can be taken at 530 nm excitation and 
590 nm emission as the amount of fluorescence detectable at these wavelengths increases in 
the reduced dye. All measurements were taken fluorometrically. The IC50 value was calculated 
by analysing the data with the IC50 value algorithm of the Grafit 4.0 software. Values were 
checked for accuracy by visually examining ceU viability and motility. Each experiment was 
performed in duplicate, and replicated at least once.
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2.5.2 In vivo Toxicity Assav
Groups of five female ICR mice Avere infected intraperitonealy with 2 x 10^  parasites. Each 
group was treated on days 2 and 3 post infection with either test compounds at the highest 
tolerated dose, berenil at 20 mg/kg, or no drug. Parasitaemias were checked daily by 
examination of a tail blood smear under phase contrast microscopy. Parasitaemia was scored 
using the rapid matching method (Herbert & Lumsden 1976). Any animal approaching 1 x 10® 
tiypanosomes/ml was sacrificed. Animals presenting no parasitaemia were allowed to 
continue in the experiment until 40 days post infection,
2.6 Fluorescence Assays
Blood was collected as previously described from ICR mice presenting peak parasitaemias. 
The parasitaemia was variable according to the infecting trypanosome strain. 0.5 pi of 10 mM 
fluorescent diamidine (DB 75, DB 544 or DAPI) was added to 500 pi of whole blood at room 
temperature to give a starting concentration of 10 pM. This was thoroughly mixed and 
approximately 2 pi removed to a glass slide and covered to produce a wet blood smear that 
was viewed over a 10-30 minute time period. This was viewed directly through the Zeiss 
Axioscop FL fluorescence microscope using a Zeiss 02 filter at an excitation wavelength of 
330 nm and an emission wavelength of 400 nm. Images were obtained by the same method, 
but using an Axiovert 200M Fluorescence microscope.
2.6.1 Blocking the development of fluorescence
The development of fluorescence was blocked by pre-incubating 500 pi of whole blood 
containing parasites with 1 mM adenosine or pentamidine for 30 seconds. The assay was then 
continued as described above.
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2.7 Molecular Techniques
2.7.1 Purification of DNA and RNA from Trvpanosomes
Bloodstream form trypanosomes were harvested from culture. RNA was extracted using 
TRIzol® Reagent (Life Technologies) using the manu&cturer’s protocol.
DNA was extmcted from a cell pellet to which was added 500 pi of lysis buffer (Appendix I). 
This was incubated overnight at 50^C. 500 pi phenol was added and incubated for 5 minutes at 
room temperature, then 500 pi of chloroform added. After mixing, the tubes were centrifuged 
at 1800 X g for 10 minutes, and the aqueous phase removed and added to 0.1 volume 3M
NaCl, 2 volumes ethanol in a 1.5 ml eppendorf. The precipitated DNA was removed and
washed in 1 ml 70% ethanol. The DNA was pelleted and most of the ethanol drained off. 
Excess ethanol was then evaporated overnight at 37°C. The DNA pellet was resuspended in 
50 pi double distilled, autoclaved water.
2.7.2 Polymerase Chain Reactions
50 pi PCR reactions were performed to amplify the TbATl gene. Each reaction contained 5 pi 
lOx reaction buffer (provided by the manufacturer), 200 pM each of dATP, dCTP, dGTP and 
dTTP, 2.5 pM each of the primers, 1.25 units of Pfu Polymerase and 200-300 ng of DNA 
template. The primers for TbATl amplification were designed to fall outwith the open reading 
frame for P2, and wers,
5’ P2F : CAT GCG CTT TGG TGG AGG 
3 ’ P2R : TTG GCG A AT CGG TGT ACG
Amplification was performed on a Gene AmpPCR System 2400 from Perkin Elmer under the 
following conditions: 5 minutes at 94°C (initial dénaturation step), followed by 30 cycles of 1 
minute at 94°C (dénaturation step), 1 minute at 60°C (annealing step) and 2.5 minutes at 72®C 
(amplification step). A final amplification step was added of 72^C for seven mmutes.
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2.7.3 Agarose Gel Electrophoresis of DNA
Agarose gels were prepared in TAB buffer (Appendix I) with 1% agarose and 0.5 pg/ml 
ethidium bromide. Gels were run in TAB buffer either at 20 mV overnight (Southern) or at 80- 
100 mV for 1-2 hours. DNA in the gels was visualised by ultraviolet light in a trans­
illuminator (UVP Laboratory Products).
2.7.4 Purification of DNA from Agarose Gels
DNA samples were run on an agarose gel alongside an appropriate DNA marker. DNA 
fragments that appeared of the right size were excised using a clean scalpel and transferred to 
a sterile 1.5 ml Eppendorf, The DNA was then extracted using a Qiagen gel extraction kit 
using the manufacturer’s instructions.
2.7.5 A-tailing Pfu polvmerase PCR Product
The pGEM-T (Promega) plasmid, which was used for all cloning, requires tlie addition of a 
single deoxyadenosine at the 3’ end of the insert, however, Pfu polymerase produces a blunt 
ended product. Pfu PCR preduct was A-tailed by combining 7 pi of product vrith 1 pi of lOx 
Taq polymerase PCR buffer with MgCb, 200 pM dATP, 5 units of Taq polymerase and dd 
water to a final volume of 10 pi. The reaction was allowed to proceed for 30 minutes at 72°C.
2.7.6 Ligation into Plasmid Vector
pGEM-T was purchased ready to use. Ligation reactions were carried out at a 3:1 ratio of 
molar ends of insert to vector, according to the manufacturer’s instructions and incubated 
overnight at 4°C.
2.7.7 Transformation of Competent Cells
JM109 competent cells of high efficiency were purchased from Promega. These were stored at 
-80^C and heat shocked according to the manufacturer’s instructions. After heat shocking.
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900 pi of LB medium (Appendix I) was added to the cells, which were then incubated at 3TC  
for one hour. The cells were then pelleted and resuspended in 100 pi of LB, then plated out on 
LB agar plates containing 50 pg/ml ampicillin, 1 mM isopfopylthio-p-D-galactoside (IPTG) 
and 50 pg/ml 5-bromo-4-chloro-3“indolyl-p-D-galactoside (X-Gal). The plates were incubated 
overnight at 37°C.
2.7.8 Plasmid DNA Preparation
Single colonies were picked from LB agar plates, transferred to 5 ml of LB medium 
containing 100 pg/ml ampicillin and incubated overnight at 37'^ C with vigorous shaking. The 
culture was then centrifuged for 10 minutes at 1250 x g and DNA extracted from the pellet 
using a Qiagen Minipiep kit according to the manufacturer’s instructions.
Plasmid DNA preparations were sent to MWG Biotech for sequencing. Primers internal to the 
TbATl open reading frame (ORF) (designed by MWG Biotech) were used to ensure complete 
double stranded coverage of the whole gene.
2.7.9 Restriction digest of DNA
Plasmid DNA was checked for inserts by restriction digest. Digestions were carried out at 
37“C, with 5 units each of restriction enzyme (PstI and EcoRI), 1 pi of lOx buffer appropriate 
for each enzyme (provided by the manuActurer), 50-100 ng of miniprep DNA and double 
distilled water up to 10 pi. DNA samples were mixed with blue sample loading buffer 
(Appendix 1), and then loaded and run on an agarose gel alongside an appropriate DNA 
marker to identify fragments of the appropriate size.
Genomic DNA was digested in 100 pi volumes using 20 units of restriction enzyme and 10 pi 
of lOx buffer. Digests were carried out at 37°C for at least 4 hours to achieve complete 
digestion.
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The Digest product was precipitated by adding 10 pi 3M NaCl, and 200 pi ethanol. This was 
incubated at -80°C for 30 minutes, and then centrifuged at 10,000 x g for 15 minutes. The 
pelletted DNA was washed in 500 pi 70% ethanol and centriftiged again at 10,000 x g for 15 
minutes. Excess ethanol was removed by pipetting and the pellet dried for 20 minutes in a 
Savant DNA 100 Speedvac. The DNA pellet was resuspended in 20 pi double distilled, 
autoclaved water.
2.7.10 Southern Hybridization
Approximately 3 pg of genomic DNA was completely digested with restriction enzymes and 
separated on a 1% agarose gel. The gel was then placed in 0.25 M HCl for 30 minutes to nick 
the large molecular weight fragments of DNA. After washing in double distilled water the gel 
was placed in 0.5 M NaOH, 1,5 M NaCl for 30 minutes to denature the DNA. Finally, after 
again washing in double distilled water, the gel was placed in a neutralisation solution of 0.5 
M Tris, pH 7.4, 1.5 M NaCl for 30 minutes. All these incubations took place at room 
temperature with gentle shaking.
DNA was then transferred to nylon membrane (Hybond N, Amersham) as described by 
Sambrook et al (Sambrook et al. 1989) using 20x SSC (Appendix I). DNA was fixed to the 
membrane using an ultraviolet cross-linking procedure (Spectrolinker XL-1000 UV linker, 
Spectronics Corporation), for optimal cross-linking.
The membrane was pre-hybridized with a hybridization solution containing 50% formamide, 
5x SSC, lOx Denhardt’s solution (Appendix I), 0.1% SDS, 20 mM NaH2P0 4 , 5 mM EDTA 
and 0.2 mg/ml of denatured herring sperm DNA, for 2 hours at 42®C, The radioactive probe to 
the full TbATl open reading fiume (as described in section 2.7.13) was then added and the 
hybridization left to continue at 42°C overnight.
The blot was then washed at 60°C for 3 x 30 minutes in wash buffer, consisting of 0.1 x SSC 
and 0.1% SDS. After washing, the membrane was wrapped in cling-film and exposed to X-ray 
film (Konica Medical Film) at -70°C for varying lengths of time. Autoradiographs were
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developed using a film processor (X-Ograph imaging system Compact X4) according to the 
manufacturer’s instructions.
2.7.11 Formaldehyde Gel Electrophoresis of RNA
Formaldehyde gels were made by mixing 9.74 ml formaldehyde, 3 ml 20x Northern gel buffer 
(Appendix I) and 17.3 mi double distilled water to 30 ml melted 2% agarose solution. The gel 
mix was allowed to solidify in a casting block and, once loaded, run in Ix Northern gel buffer 
consisting of 25 ml 20x northern gel buffer, 45 ml formaldehyde and 430 ml double distilled 
water.
RNA samples were prepared by adding 1 pi of 20x Northern gel buffer, 3.5 pi of 
formaldehyde, 10 pi of formamide and double distilled water to a final volume of 20 pi. The 
samples were heated to 55°C for 15 minutes then chilled on ice. 2 pi of RNAse firee loading 
buffer (Appendix 1) was added and the samples loaded onto the gel. The gel was run 
overnight in a fume hood at 25 V.
2.7.12 Northern Hybridization
Approximately 4 pg of RNA was electrophoresed under denaturing conditions on a 
formaldehyde gel. The gel was then directly blotted onto a nylon membrane and treated as 
described for the Southern Hybridization in section 2.7.10, above.
2.7.13 Labelling of DNA Probes
Approximately 200 ng of a gel purified, cloned insert of the TbATl open reading frame was 
labelled with using the Stratagene Prime-It II random primer labelling kit, according to 
manufacturer’s instructions. The labelled probe was then purified using a spin column 
(Microspin TM S 200HR, Amersham Pharmacia Biotech) using the manufacturer’s 
instructions. Total recovered labelled DNA was then heated to 95°C for 5 minutes to denature, 
and added to the hybridization buffer, regardless of membrane size.
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2.8 Software
Biochemical kinetic data was handled using Grafit 4.0 (Erithracus Software). This included 
the determination of kinetic inhibition constants and IC50 values.
DNA and protein sequences were handled using the Vector NTI suite 6 package (Informax). 
This package includes ContigExpress for creating continuous sequences from overlapping 
contigs. Vector NTI for handling the DNA and protein sequences and AlignX for aligning 
nucleotide and protein sequences.
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Chap te r  III. Polyamine A nalogues Bearing the P2 Recognition M o tif a s Targeted Trypanocides
3.1 Introduction
Polyamines are essential for normal growth, maintenance and development of all cells, 
regardless of their origin. Any interference with polyamines, by blocking their production or 
functions, reduces cell viability, eventually leading to cell death. Targeting polyamine 
synthesis in trypanosomes additionally blocks the production of the parasite specific enzyme 
trypanothione. The absence of trypanothione fi'om the cell leaves the trypanosome vulnerable 
to attack fi'om oxidative stress (Krieger et al. 2000).
Trypanosome polyamine metabolism has already been validated as a drug target by the 
chemotherapeutic activity of the compound DL-a-difluoromethylomithine (DFMO) against 
infections of T.6. gambiense. DFMO disrupts polyamine synthesis by acting as an irreversible 
inhibitor of ornithine decarboxylase, blocking the polyamine synthesis pathway at the point of 
putrescine synthesis (Giffin et al. 1986) (Figure 3.1).
Ornithine
IFMO 'iifiiiniiii |!it>
Putrescine
dAdoMets.
Ado-S-MetA^
Spermidine 
G s e - ^
Gluathionylspeimidine 
 -----
Trypanothione
Figure 3.1. Polvamine biosvnthetic path wav in African trypanosomes.
Reproduced from Fairlamb, A . H ., 1997.
By introducing polyamine analogues into a cell it may be possible to compete with that cell’s 
indigenous polyamines and disrupt their synthesis and/or function(s) within the cell. African
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trypanosomes however, apparently lack any type of transporter for polyamines, all their 
polyamine requirements being met by de novo synthesis (Fairlamb & Le Quesne 1997).
The P2 transporter is normally responsible for the uptake of adenosine and adenine but has 
also been shown to mediate the uptake of various trypanocidal compoimds (Carter et al. 1995). 
All compounds taken up by P2 contain a molecular motif that is recognised by the transporter 
and to which the transporter associates prior to uptake (de Koning & Jarvis 1999). Figure 3.2 
illustrates the P2 recognition motif, H2N-C(Ri)=N(R2), on adenosine and various 
trypanocides.
OH OH
Adenosine
CHjOH
Melarsoprol
NHj
NH,
Pentamidine
HnN Polyamine analogue
Melamine ;
transport
unit
Figure 3.2. Adenosine, pentamidine, melarsoprol and melamine 'transport unit’.
The primary P2 recognition motif, H2N-C(Ri)=N(R2 ), is shown in red.
In order to introduce selective uptake of polyamine analogues in trypanosomatids, a 
recognition motif for the P2 transporter, in the form of a melamine ring attached via a 
methylene linker, was added to a variety of polyamine analogues, in the hope it would act as a 
‘transport unit’ (Figure 3.2).
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Preliminary work in this area was carried out by Tye and coworkers, on a limited series of 
polyamine analogues. These analogues were linked to the P2 recognition motif in the form of 
derivatives of one or more triazine rings. The published results showed that these compounds 
at least associated with the P2 transporter to limit adenosine uptake, and that some showed 
limited toxicity to T. b. brucei in vitro (Tye et al. 1998).
3.1.1 Synthesis of PoKamine Analogues
Burkhard Klenke synthesised all compoimds at the Welsh School of Pharmacy, Cardiff 
University. Each compound consisted of a polyamine analogue core unit attached to various 
differently substituted 1,3,5-triazines as transport units aimed at interacting with the P2 
transporter (Fig. 3.3).
Rf link
V r
core unit
___ A
Rl
R. transportunit
central core unit 
n = 0, 1
R!-K'= H, alkyl
J— Ra
transport / — Rl
Figure 3.3. General structure of experimental compounds.
Four groups of compounds, which could be distinguished by variations of their core unit 
and/or transport units, were synthesised. Their structures are shown in Figure 3.4.
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3.2 Results
3.2.1 Interaction with the P2 Transporter
All compounds showed dose-dependent inhibition of adenosine uptake via the P2 transporter 
(Table 3.1). Apparent Ki values were calculated using the competitive inhibition equation from 
the Grafit 4.0 software. Examples are shown in Figure 3.5.
Compound P2 affinity 
Ki(pM)
Toxicity in vitro 
IC50 (pM)
5a 72 +/- 5 >100
5b 19 +/- 0.6 >100
5c 0.5 +/- 0.2 >100
5d 148 +/-12 >100
5e 55 +/-1.14 >100
5f 125 +/- 38 >100
6a 0.75 +/- 0.25 50.4 +/- 8.2
6b 1.0 +/-0.02 39.6 +/- 1.9
6c 14 +/- 1.67 3.9+/-0.7
6d 28.8 +/- 0.94 25.2 +/- 8
6e 0.135+/-0.004 2.0+/-1.5
6f 0.25 +/- 0.05 >100
6g 3.2+/-1.4 17.4+/-4.4
6h 2.5 +/- 0.2 1.67 +/- 0.5
7a 14+/-2 68+/- 24
7b 0.5+/-0.12 >200
7c 1.1+/- 0.1 19 +/- 2.9
7d 26.2 +/- 0.37 21.3 +/-17
7e 0.6 +/- 0.3 14.7 +/- 1.86
8a 82.8 +/-10.4 35.5 +/- 3.9
8b 16.78+/- 0.11 3 +/- 0.32
8c 30.2 +/-0.3 0.11 +/-0.3
8d 6.7 +/- 0.5 21.2+/-10.1
8e 4.55+/-2.5 2.0+/-1.5
8f 2.37 +/- 0.42 2.9 +/- 0.29
Putrescine n/a 60 +/- 11.2
Spermine n/a 5.51+/- 0.08
Spermidine n/a 10.44+/-0.1
Table 3.1. Inhibition of adenosine uptake and toxicity of polvamine analogues. 
Results are shown +/- standard error, n = 2.
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6e
Ki = 0.135 ^iM
<  CL,
[Adenosine] \iM
No inhibitor 
0.1 uM inhibitor 
1 uM inhibitor 
10 uM inhibitor
Ki = 0.25 pM
[Adenosine] jaM
No inhibitor
0.1 uM inhibitor
1 uM inhibitor
10 uM inhibitor
Ki = 30.2 nM
[Adenosine] \iM
No inhibitor 
1 uM inhibitor 
100 |iM inhibitor 
1000 i^M inhibitor
Figure 3.5. Examples of Grafit calculated Ki values.
Apparent K, values were calculated using the competitive inhibition equation from the Grafit 4.0 software. 
Double reciprocal plots are shown as inserts.
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The double reciprocal Lineweaver Burke plots as illustrated in Figure 3.5 (inserts) are typical 
in that a downward slope is apparent in the data points for the lowest concentrations of 
substrate. This result could be due to contamination of the samples. Another possibility is that 
the presence of multiple adenosine transporters in the trypanosomes has affected the data. 
However, the experiments were carried out in the presence of 1 mM inosine (which blocks the 
PI transporter) and with adenosine concentrations at or below 5 pM. Under these conditions 
the amount of adenosine that enters the cells through components other than P2 has been 
shown to be negligible (de Koning & Jarvis 1999), which does not agree with the multiple 
transporter theory. The reason for the downwardly sloping plots has not been further 
investigated due to time constraints.
The series of compounds 5a-5c show an increase in apparent affinity for the P2 transporter 
associated with an increase in chain length. Non-polyamine-like core units such as in 5d-f 
result in a decrease in affinity. It is not certain why the polyamine analogues, or their central 
chain length, should be important in the affinity of the compounds for the transporter. One 
possibility is that chain length affects the length of time each molecule occupies a transporter’s 
binding site, or the time taken for the carrier to transport the molecule across the cell 
membrane and return to its native state (see discussion). There is no data to confirm that these 
compounds actually enter into the cells via P2 since the assay simply measures their ability to 
inhibit adenosine uptake, making it impossible to speculate on their transport.
In series 6a-h, a comparison of the (CH2)9 compounds to their corresponding (CH2)i2 
compounds shows that, as before, an increase in core unit chain length results in an increase in 
P2 apparent affinity. The increase in apparent affinity is not consistent across the series, being 
between 4 and 40 fold. Apparent affinity for P2 is consistently greater in the compounds 
bearing one monomethylated or dimethylated melamine amine on each transport unit than for 
their unmethylated counterparts, 5b and 5c. Any more methyl groups added to the remaining 
amine group results in a decrease in apparent affinity. This decrease in apparent affinity when 
both amine groups are methylated is as expected as the addition of methyl groups acts to 
disrupt the primary P2 recognition motif, H2N-C(Ri)=N(R2).
51
" I
_________________________________________ Chapter III. Polyconine Analogues Bearing the P2 Recognition M otif a s Targeted T rypam cides
The unexpected increase in apparent affinity in the monosubstituted compounds 6a and 6e as 
compared with 5b and 5c may be due to the effect of the methyl groups on the 7c-orbitals 
within the triazine ring. As suggested in work published by de Koning (de Koning & Jarvis 
1999), a high binding affinity for the P2 transporter requires an aromatic system on the 
substrate. It is proposed that the Ti-orbitals of the substrate stack with the 7t-orbitals of an 
aromatic residue within the substrate binding site to increase the binding energy of the 
interaction and stabilise the bond. This ti-orbital stacking has been shown to play a role in 
other systems, such as in the binding of purines to the purine nucleoside phosphoiylase (PNP) 
(Koellner et al. 1998) and phosphoribosyltransferase (Vos et al. 1998) o f Escherichia coli. The 
forces between two interacting ji-systems can reach 10 kJ/mol or more under optimal 
conditions (Hunter et al. 1991) and so contribute greatly to the affinity of a substrate for an 
enzyme.
It is possible that the methyl substitution of one amine group might increase the electron 
density in the compound’s 7r-system. This could potentially increase the contribution of tt- 
stacking to the binding of the compound, while leaving one amine group open as the primary 
recognition motif for the transporter.
The series 7a-e consists of polyamine analogues attached to just one melamine ring, resulting 
in an asymmetrical compound. Only one compound in this series contains a 9 carbon chain 
(7a), the rest have 12 carbon chains. The measured apparent affinity of 7a is greater than that 
of its comparable 12 carbon compound 7d, their apparent Ki values being 17 pM and 25 pM 
respectively. This is contrary to the general trend, but the difference is less than two fold and 
is therefore not a substantial difference in apparent K, value. The monosubstituted 
monomethylated compound 7b has the greatest affinity for P2, fitting in with the previously 
established pattern in series 6. The monosubstituted dimethylated compound 7c, and the 
disubstituted dimethylated compound 7e have the next highest affinity for P2, their apparent 
Ki values being 1 pM and 0.6 pM respectively.
The series 8a-f follows the previous trend in that the 12 carbon chain compounds show greater 
affinity than the 9, and that methylated compounds show greater apparent affinity than
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unmethylated compounds, although 8e and 8f have similar Ki values. There does not appear to 
be any advantage to the extra melamine ring attached via an extra methylene bridge, and 
affinity is reduced when compared to equivalent compounds bearing just one melamine ring,
3.2.2 Trypanocidal Activity in vitro
3.2.2.1 Trypanocidal activity against T. b. brucei 427
Results for in vitro activity are shown in Table 3.1. Examples of IC50 graphs are shown in 
Figure 3.6.
Q g Compound 5c
I C 5 0  >  1 0 0  ^ i M
 ^ 0.6
[5c] pM
10%
I
Q g Compound 7c
0.7
0.6
0.5
[7c] pM
Compound 8b0.8
R 0.7
•2■3 110' 11010
[8b] pM
Figure 3.6. Examples of Grafit calculated ICsn values.
Absorbance o f  Alamar Blue at 570 nm was plotted against concentration o f  drug, and an 1C50 calculated from 
Grafit software.
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The length, or even the nature, of the central core unit of the compounds tested does not 
appear to affect the toxicity of that compound. The only general pattern observed is that 
methylated compounds are more toxic. In general, the greater the number of methyl groups 
present on the compound, the greater their trypanotoxicity. Most of the compounds tested 
showed insufficient toxicity to be useful as trypanocides. The exceptions to this are 6 c, e and 
h, and 8 b, c, e and f. These compounds have I C 5 0  values in the range of 0.1-4.0 pM.
3.2.2.2 Activity against ATbatl (P2 knock outl cells
The experimental compounds 6e, 8b, 8c and 8e were tested for activity against T. b. brucei 
strain MiTat 1.2 (BS221), and a ATbatl null mutant constructed from this line which lacks P2 
activity (Enock Matovu, unpublished data). If the compounds are taken up into the cells via 
the P2 transporter, it was anticipated that the mutant cell line lacking the transporter would 
display some degree of resistance as compared to the parent cell line. The results are shown in 
Table 3.2.
Compound Toxicity in vitro IC50 (pM) Resistance
FactorTbATl cells ATbatl cells
6e 114 74 0.64
8b 2.9 4.7 1.62
8c 0.9 0.9 1
8e 0.6 0.9 1,5
Table 3.2. In vitro activity against TbATl and ATbatl cells.
Resistance factors represent the differences in activity o f  the compounds in different cell lines.
All of the compounds show very little or no difference in toxicity between TbATl and ATbatl 
cell lines. This suggests that although the compounds do interact with the P2 transporter to 
inhibit adenosine uptake, the toxicity observed is not dependent on uptake of these compounds 
via the P2 transporter. The differences in toxicity exhibited between these cell lines and the T 
b. brucei 427 line are most likely to be due to strain differences.
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3.2.3 In vivo Activity
Based on their apparently high affinity for P2 and their low IC50 in vitro, as well as a degree of 
selective toxicity towards trypanosomal cells as compared to L-6 rat myoblast cells in vitro 
(Table 33), compoimds 6e, 8b, 8c and 8e were selected for testing in vivo.
Compound Z! brucei 421 
IC50 (uM)
T. b. rhodesiense 
I C 5o ( u M )
T. cruzi 
IC50 (pM)
L-6 rat myoblast 
cells IC50 (pM)
6e 2.0 9.8 116 nd
8b 3.0 0.265 54.8 177
8c 0.1 0.265 76.8 177
8e 2.0 0.44 >77 105
Table 33 Comparative toxicities of 6e. 8b. 8c and 8e.
T. b. rhodesiense STIB 900, T . cruzi Tulahuen C4 and L-6 rat myoblast cell data supplied by Reto Brun, Swiss 
Tropical Institute, Switzerland, 
nd = not defined.
It was found, however, that a dose of 1 mg/kg was not curative, and a dose of 10 mg/kg 
induced severe adverse reactions in mice, precluding further investigation,
3.3 Discussion
In the above results apparent Ki values have been taken as an indication of the affinity of a 
compound for the P2 transporter. In experiments, Ki values for these compounds were 
obtained by measuring the degree to which they inhibit the uptake of a different, labelled, 
substrate for the same transporter. Relating Ki values measured in this manner to the inhibiting 
substrates’ affinity for the transporter should be done with caution. A Ki measured in this way 
is dependent on the amount of time that the inhibiting compound is associated with a 
transporter and is blocking the uptake of labelled substrate. This is in turn influenced by the 
time taken for the inhibitor to travel across the membrane and be released on the other side, 
and how long it takes for the transporter to reconfigure itself to be able to receive another 
molecule. The longer each inhibitor molecule is associated with the transporter and blocking 
the uptake of the labelled substrate, the lower the Ki will appear. Tins means for example that 
a compound with a low affinity that travels across the membrane slowly may appear to have 
the same Ki as a compound that has a high affinity but a fester turnover. Notwithstanding the
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limitations of inhibition studies as a means to infer affinity, such studies are in wide use and 
can be used as a basis to measure affinity.
The results for these polyamine analogues show that the addition of a P2 recognition motif has 
produced a series of compounds which block adenosine uptake via the P2 transporter and in 
some cases show toxicity in vitro. There is no indication as to whether any of these 
compounds are actually transported into the cell via P2, only that they associate with the 
transporter in some way. Neither is there any correlation between the toxicity of a compound 
and its interaction with the P2 transporter. Additionally, a ATbatl cell line, which lacks P2 
activity, gained no advantage over a wild type cell line in toxicity studies. This implies that 
transport via P2 is not critical for the uptake of these compounds into the cell or for their toxic 
effects. Other mechanisms of uptake, interactions with intracellular targets or toxic effects 
caused by interactions at the cell surface are probably more important in determining toxicity. 
This concurs with the findings of Tye et al on a smaller series of related compounds (Tye et al.
1998).
Although a few of the compounds are highly toxic to T. b. brucei in vitro, neither their 
intracellular target(s) nor their mechanisms of action are known. Toxicity could potentially be 
an artefact of the breakdown of the polyamine analogues outside the cell, and the toxicity of 
their breakdown products. Polyamine oxidase, present in bovine serum, has previously been 
shown to mediate trypanolytic activity when incubated with exogenous polyamines (Traore- 
Leroux et al. 1987). The polyamines spermidine and spermine (Table 3.1) were shown to be 
toxic in vitro at concentrations less than those inside trypanosomes, but in the same 
concentration range as the polyamine analogues. Polyamine oxidase could also potentially 
break down the polyamine analogues to toxic by products that affect cell viability in vitro.
The quantity of product supplied did not allow for a study of breakdown products. An attempt 
to investigate the toxicity of the separate transport unit portion of the compounds was made 
using fi*ee melamine rings, but these were found to have very poor solubility in aqueous 
solution making it impossible to measure their toxicity with any accuracy.
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4.1 Introduction
Further to the work detailed in Chapter in, three more groups of potentially trypanocidal 
compounds, all of which carry the P2 recognition motif, were tested for their abilities to 
interact with the P2 transporter and their toxicity to T, b. brucei 427. The first group of 
compounds was selected with the assistance of Dr. R. A. Hill (Department of Chemistry, 
University of Glasgow), firom The Combined Chemical Dictionaiy on CD-ROM version 5.2, 
Chapman and Hall, CRC Press, 2002. They were identified fi-om the database by searching for 
the primaiy P2 recognition motif, H2N~C(Ri)=N(R2) within the structure of the compounds.
The HIV gpl20 binding mimetics, and the nitrofuran and nitroimidazole groups of compounds 
were synthesised by Burkhard Klenke, Cyrille Boussard and Gorka Jimenez-Bueno at the 
Welsh School of Pharmacy, Cardiff University.
4.1.1 Database Compounds
Out of the many compounds identified, 6 were chosen on tlie basis of their likely toxicity and, 
importantly, their availability. These compounds are described and illustrated below.
Antipain. An oligopeptide antibiotic originally 
isolated fi-om Streptomyces spp. Antipain is 
commonly used as a protease inhibitor, 
inhibiting trypsin-like serine and some cysteine 
proteases, but has also been shown to have some 
effects in suppressing experimental 
carcinogenesis.
Canavanine. Originally isolated from the 
Jackbean, this compound is found in the seeds of 
three subfamilies of leguminous plants. It has 
insecticidal properties, and has additionally been
HO-CHj
O - C - C - 0 — N
N H N HH O
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shown to have antineoplastic, antibacterial and 
antifungal properties.
Dihvdrostreptomycin. Obtained by the reduction 
of streptomycin, this aminoglycoside antibiotic 
was originally isolated from Streptomyces 
humidus. It is a broad spectrum antibiotic, but 
has been restricted to veterinary use due to likely 
ototoxicity.
Distamvcin A. This antiviral agent is used 
topically to treat herpes simplex infections. It is 
a peptide antibiotic isolated from Streptomyces 
distallicus.
N  OH
CH.OH
CI^OH
CH NH
NH
Leupeptin. As for Antipain, Leupeptin is 
commonly used as a protease inhibitor, 
inhibiting trypsin-like serine and some cysteine 
proteases. It is a peptide antibiotic produced by 
many Streptomyces spp, and shows antiplasmin 
and anti-inflammatory activity.
Octopine. Octopine is isolated from aqueous 
extracts of the tentacle muscles of Loligo pealii 
and Octopus vulgaris^ as well as from the 
adductor muscles of the scallop Pecten 
magellanicus and the muscles of the octopod 
Eledone moschata.
NH2
<pH(CH3)2 (^ :h (c h 3)3
9H3 <pH2
K o "N  C— n— N H H 5 H
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4.1.2 HIV gpl20 Binding Mimetics
As the name suggests, these compounds were originally designed for a separate project that 
aimed to stop HIV invasion of a host cell. A peptide library was constructed vriiich mimicked 
the CD4 marker on the cell surface with which the HIV protein gpl20 interacts. Following this 
interaction, gpl20 undergoes a conformational change and interacts with a chemokine 
receptor. Another HIV protein, gp41, now penetrates the cell membrane and fiision takes place 
(Boussard et al. 2002). Having discovered some small peptides that mimicked CD4, further 
simplified compounds were made which incorporated the most important groups on CD4 for 
the interaction.
These compounds carry the P2 recognition motif in the form of a benzamidine group, with the 
exception of WSP 670, which has a melamine substitution (Figure 4.1), and 509 and 510 
which carry guanidine groups. This afforded us the opportunity of investigating the feasibility 
of using a benzamidine motif in order to target compounds to the P2 transporter.
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Figure 4.1. Structures ofHTV gpl20 binding mimetics.
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4.1.3 Nitrofiiran and Nitroimidazole Compounds
Nitroheterocyclic compounds are broad-spectrum antimicrobial agents, ordinarily used in the 
treatment of infections caused by anaerobic protozoa and bacteria. Nitrofurans are commonly 
used in human and veterinary medicine to treat giardiasis (Boreham et al. 1991), typhoid 
(Carcelen et al. 1989) and cholera (Rabbani et al. 1991). The 5-nitrofiiran, Nifiirtimox is used 
to treat infections of Trypanosoma cruzi, the causative agent of Chagas disease (DoCampo et 
al. 1981). Nifiirtimox has also been suggested for use in cases of melarsoprol-refractoiy T 
brucei infections (Pepin et al. 1992).
The 5-nitroimidazole compound. Metronidazole is used to treat Giardia intestinalis, 
Trichomanas vaginalis and Entamoeba histolytica, and also as a treatment for, or as a 
prophylactic against, many anaerobic bacterial infections (Townson et al. 1994). The 2- 
nitroimidazole, Benznidazole is used to treat Chagas disease (Rodriques & de Castro 2002). 
More recently Megazol, a 5-nitroimidazole, has been shown to have activity against T. cruzi 
(Filardi & Brener 1982), and is also effective in clearing experimental T. brucei infections 
when used with suramin or melarsoprol (Enanga et al. 1998).
The activity of the nitroheterocyclic compounds is mainly attributed to the reduction of their 
nitro group to form the nitro anion firee radical (NO2 ”). This reactive species may then exert 
its toxicity by interacting with parasite macromolecules, or by reacting with oxygen to produce 
reduced oxygen by-products such as O2 " or H2O2 that could cause oxidative stress within the 
cell. Tiypanosomatids are more vulnerable to oxidative stress as they lack catalase and 
glutathione peroxidase, and rely on the parasite-specific enzyme trypanothione reductase to 
maintain an intracellular reducing environment (Fairlamb & Le Quesne 1997; Krieger et al. 
2000).
Nitroheterocyclic compounds exhibit a range of side effects, which are the result of 
mammalian cells also having the ability to reduce nitroheterocyclic compounds to release 
toxic metabolites. The side effects are limited, however, by the increased ability of
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mammalian cells to protect themselves from oxidative stress and, perhaps, by changes in 
selectivity of nitroreductase activities in cells.
Selective uptake into the parasite, in principle, offers another means of ensuring activity 
against the trypanosome but not the host cells. A P2 recognition motif has been added to our 
test compounds with the intention of targeting the compounds more specifically to 
trypanosomes and in an attempt to reduce some of the toxic side effects in the host.
The nitrofiiran compounds in this group carry the P2 recognition motif in the fonn of a 
melamine group (Figure 4.2, compounds 719,744 and 745), substituted in the same way as the 
polyamine analogues described in the previous chapter. Compounds 746 and 747 consist of 
the melamine transport unit alone, with no nitro group (Figure 4.2), Compounds, 748 and 749, 
which have no recognition motif for P2, were included as controls (Figure 4.2), The 
nitroimidazoles cany either a benzamidine motif occluded by a r-butanoic acid group (Figure 
4.2, compounds 817 and 836), or an open benzamidine (Figure 4.2, compounds 854 and 855).
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Figure 4.2. Structures of Nitrofiiran and Nitroimidazole Compounds.
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4.2 Results
An IC50 for the inhibition of adenosine uptake was measured for all compounds in order to 
determine the optimum range of adenosine concentrations to use in subsequent experiments to 
derive apparent Kj values. If compounds showed little promise of P2 interaction at this stage, it 
was not deemed necessary to continue the uptake experiments.
4.2.1 Database Compounds
The results for these compounds are summarized in Table 4,1,
Compound Inhibition of adenosine 
transport, IC50.
Toxicity in vitro
Antipain No inhibition at 1 mM None at 200 pM
Canavanine No inhibition at 1 mM None at 200 pM
Dihydrostreptomycin No inhibition at 1 mM None at 200 pM
Distamycin A 10.6 pM None at 200 pM
Leupeptin No inhibition at 1 mM None at 200 pM
Octopine No inhibition at 1 mM None at 200 pM
Table 4.1. Inhibition of adenosine transport and toxicitv of database compounds.
A ll the above experiments w ere carried out on the T. brucei 427 cell line.
The only compound to show any interaction with P2 was Distamycin A. With the exception of 
Dihydrostreptomycin and Distamycin A, all the compounds lack any aromatic ring structure 
which plays an important part in forming attachments with the transporter (de Koning & Jarvis
1999). The large size and bulky stmctures of these compounds may further contribute to their 
lack of interaction with the P2 transporter.
Also of note is that of all compounds, Distamycin A, is the only compound to carry the P2 
recognition motif in the form of an amidine group. The motif on the other compounds occurs 
as part of a guanidine group. For reasons detailed in the following section, this structural 
group reduces afiSnity for the P2 transporter. Additionally, Distamycin A carries its amidine 
group at the end of a carbon chain, which allows it more flexibility in movement, and may
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assist it in associating with the transporter. That Distamycin A should be able to inhibit 
adenosine uptake via P2 to a moderate extent is apparent, but a lack of toxicity in vitro made 
further investigation redundant.
4.2.2 HIV gpl20 binding mimetics
Results for these compounds are shown in Table 4.2.
C o m p o u n d I n h i b i t i o n  o f  
a d e n o s in e  t r a n s p o r t ,  
IC 50 (pM)
T o x ic i ty  in vitro. IC50 (pM) R e s i s ta n c e
F a c to r427 TbATl ATbatl
509 9.3 57 52 79 1.52
510 8.05 109 111 128 1.15
670 0.38* 96 97 258 2.65
707 0.38 54 33 44 1.33
708 0.38 56 37 60 1.62
709 0.81 10 6 7 1.06
710 0.33 66 58 71 1.22
711 0.21 14 10 28 2.80
712 1.01 13 11 14 1.27
713 1.57 7 8 12 1.50
Table 4.2. Inhibition of adenosine transport and toxicitv of HIV gpl20 binding mimetics.
*The figure for 670 is a calculated apparent Kj value,
4.2.2.1 Intemction with the P2 Transporter
All of the above compounds, with the exception of 509 and 510, which carry a guanidine 
group, have very high apparent afiinities for the P2 transporter. Only a handful of the 
polyamine analogues showed apparent affinities in the same range and the nitrofuran and 
nitroimidazole group has no compounds within 10-fold of this range of affinities.
Compounds 509 and 510 are identical to compounds 708 and 707 respectively, except they 
carry a guanidine group in place of the amidine. This factor alone apparently accounts for 24- 
fold and 21-fold differences in apparent affinity for P2. This may be explained by the spatial 
positioning of the P2 recognition motif with respect to the benzene ring. The primary nitrogen 
of the guanidine in compounds 509 and 510 is pyramidal in structure whereas the amidine 
groups on the benzamidine compounds are planar. The P2 recognition motif in a guanidine
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group is held rigidly and at such an angle as to make association with the P2 transporter 
molecule more difficult. The spatial differences are illustrated in Figure 4.3.
509,
Benzyl-guanidine
708,
Benzamidine
Figure 4.3. Spatial configuration of the P2 recognition motifs of 708 and 509.
The guanidine is pyramidal and holds the amidine portion at a set angle to the benzene ring. The amidine group 
in the benzamidine is planar.
Compoimds 670, 707 -  713 all exhibit IC50 values in the range of 0.38 -  1.5 pM which, on 
average, are higher affinities for P2 than have been measured for compoimds firom the other 
groups in this study. The benzamidine and benzene groups in compound 708, in association 
with the electronegative oxygen atom, might be able to form a conjugated 71-system, which in 
turn might contribute to affinity. However, the energy attributable to a conjugated 71-system 
cannot account for such a large increase in apparent affinity. Furthermore, compound 707, 
which has an additional carbon atom between the 2 benzene rings, has the same affinity for P2 
as does 708 even though a conjugated n system is unlikely. The same can be seen in the 
diaminopyrimidine 670 which, lacking the electronegative oxygen between the benzene rings 
to contribute to a conjugated n system, is also unlikely to have this extended system.
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The compounds 709 and 712 have an addition halogen attached to the end benzene ring, and 
this appears to very slightly reduce their apparent affinities for P2. Why the additional halogen 
should affect their interactions with P2 is unknown. Compound 713 also has a lower apparent 
affinity for P2. With three benzene rings in this compound, it may be the bulk of this 
compound that is interfering with substrate/transporter interactions.
4.2.2.2 Trypanocidal Activity in vitro 
Results are listed in Table 4.2.
All of the compounds displayed disappointingly low toxicities to T, brucei 427 in vitro. This 
precluded any in vivo trials. However, because the very high apparent affmities for P2 
displayed by the compounds might represent a high specificity for uptake via P2 they could be 
interesting lead compounds. In order to investigate this further the compounds were tested 
against the P2 transport deficient ATbatl cell line, and its parent cell line, TbATl, that has a 
normal P2 adenosine transport phenotype.
At best the compounds showed a 2.6-fold resistance factor, most being well under 1.5-fold 
less active in the ATbatl cell line. This result would indicate that the compounds do not rely 
solely on tlie P2 transporter to gain access into the trypanosome cell. There may be other 
transporters involved, for example the high and low affinity pentamidine transporters (HAPTl 
and LAPTl ), or the compounds may enter the cells by diffusion.
That diffiision may be involved is given more strength when considering the lipophilicity of 
the compounds. They all contain two veiy hydrophobic benzene residues, and those with the 
least difference in toxicity between TbATl and ATbatl cell lines, 709 and 712, are those that 
contain the halogen extensions which, carrying very little charge, might also contribute to 
lipophilicity. If this were the case, any high specificity for P2-mediated uptake that the 
compounds may have, would be concealed by the diffusion component in this three-day 
experiment.
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709 and 712 are the most toxic compounds in this group, along with 713 carrying three 
benzene rings. Apart from a potential increase in lipophilicity in these compounds, and 
therefore an increased rate of entry into the cell, the reasons for their increased toxicity are not 
clear.
4,2.3 Nitrofuran and Nitroiinidazole Compounds
Results for these compounds are shown in Table 4.3.
Compound Ki or IC50 (pM) Toxicity in vitro. IC50 (pM) ResistanceFactor427 TbATl ATbatl
719 129 0.4 0.2 0.3 1.5
744 53.4 0.36 0.41 0.66 1.60
745 4.6 6.7 11.9 14.8 1.24
746 11.9* None at 200 pM
747 59.3 None at 200 pM
748 404 10.7 23.5 13.7 0.58
749 No inhibition at 1 mM 2.6 1.1 1.2 1.09
817 13.09 62.7 111 119 1.07
836 3.65 None at 200 pM
854 1.58 97.8 >200 191
855 2.88 None at 200 pM
Table 4.3. Inhibition of adenosine transport and toxicitv of nitrofuran and nitroimidazole
compounds.
*This value is an IC 50 value.
4.2.3.1 Interaction with the P2 Transporter
Within the nitrofijran group, 745, with one methyl group attached to each melamine amine, 
has the highest apparent affinity for P2. 744, which carries an undisturbed P2 recognition 
motif, has an apparent affinity 11 times less than 745. This pattern of increased affinity in 
compounds bearing monomethylated amine groups is also seen in the polyamine analogues 
described in Chapter HI. The addition of more methyl groups in 719 acts to further disrupt the 
P2 recognition motif and the apparent affinity of this compound for P2 drops considerably.
746 and 747 do not carry any nitro groups, but are included in this group as they are the 
transport recognition portions of the compounds 744 and 745. These compounds behave in the
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opposite way to the nitrofurans and the polyamines in that 747, with the monomethylated 
melamine amines, has less affinity for P2 than 746 with an open primary P2 recognition motif. 
The 2-nitrogen chain may be involved in some interactions with P2, but no fiirther explanation 
of this unexpected behaviour presents itself. 748 and 749 lack any P2 recognition motif at all, 
and as such they have veiy little or no affinity for P2.
The nitroimidazoles carry benzamidine groups as their P2 recognition motifs. 817 and 836 
have a t-butanoic acid motif attached to the benzamidine amine group, and 854 and 855 
respectively are their r-butanoic acid free derivatives.
The compounds, 817 and 836, with the disrupted P2 recognition motiis are less able to 
associate with the transporter than their respective benzamidines, 854 and 855. They do, 
however, have moderate affinities for P2, signifying that they are still able to associate with 
the transporter, even with the t-butanoic acid group attached to the benzamidine ring.
4.2.3.2 Trypanocidal Activity in vitro
In terms of toxicity the nitrofuran compounds were very much more active (100-fold or more) 
than the nitroimidazoles. Toxicity is not dependent on the presence of a functional P2 
transporter as compounds were as toxic to P2 deficient ATbatl cells as to TbATl. Also, 748 
and 749, without any P2 recognition motif, were just as toxic as 744 and 745, again indicating 
that uptake via the P2 transporter is not critical in the toxic actions of these compounds. There 
is a possibility that the compounds may bypass any active transport system and gain access 
into the cell by diffusion. Other nitroheterocyclic compounds have already been shown to act 
in this way, e.g. Megazol (Barrett et al. 2000) and Nifiirtimox (Tsuhako et al. 1991).
The compounds 744 and 745 were carried forward into in vivo trials.
4.2.3.3 Trypanocidal Activity in vivo
744 and 745 were tested in ICR mice at concentrations of 40 mg/kg. The compounds were 
introduced intraperitoneally on the second and third days after infection with T. b. brucei 427. 
The dose was restricted by the amount of compound available for testing.
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Treatment with 744 resulted in four animals in the study group clearing infection temporarily 
from the bloodstream. These animals relapsed 7-14 days later and were sacrificed. One animal 
stayed clear of infection for up to 40 days (Table 4.4). A dose of 40 mg/kg was well tolerated, 
with no apparent side effects. It remains possible that a higher dose would have been able to 
clear the infection in all the study animals.
745 showed no in vivo activity (Table 4.4) at the dose used.
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4.3 Discussion
That a guanidine group is less effective for targeting compounds to the P2 transporter is 
apparent from the above results. Guanidine compounds were among the first drugs to be 
designed to treat trypanosomiasis, Synthalin (decamethylene diguanidine. Figure 4.4) being 
the most effective. At therapeutic levels they were thought to reduce glucose levels in the 
bloodstream of the host, and so starve the parasitic cells of this essential nutrient (Schoenbach 
& Greenspan 1948). It was quickly discovered, however, that diamidine compounds, such as 
N-undecane 1-11 diamidine (Figure 4.4), were more effective and less toxic (King et al. 1938). 
In 1942 the amidine groups were further substituted for the aromatic benzamidine group 
(Ashley et al. 1942) to eventually produce pentamidine, which is still used in tiypanosome 
chemotherapy today. This group also observed that any slight change in the benzamidine ring 
reduced the toxicity of their compounds.
NHr
HN NH
Synthalin
H.
HN NH
N-undecane 1-11 diamidine
HN Pentamidine NH
Figure 4.4. The structures and evolution of diamidine trvnanocides.
Guanido compounds were superseded by the diamidines, which in turn led to the development o f  aromatic 
diamidines.
The loss in affinity for P2 may be attributable to the rigidity of the P2 recognition motif in the 
guanidine compounds, and its position relative to the benzene ring. The amidine portion is 
held rigidly at an angle to the benzene (Figure 4.3). The P2 recognition motif and the n 
orbitals are now on different planes, vriiich could either shield the recognition motif from the 
transporter, or physically block % stacking interactions, or indeed both.
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The benzamidine compounds in this study also show a 10-fold greater affinity for P2 than 
most of the melamine bearing compounds. 670 is an exception to this, as are 6 of the 
polyamine compounds, these being 5c, 6a, 6e, 6f, 7b and 7e, which are discussed in the 
preceding chapter. Interesting to note is that pentamidine, which carries a benzamidine motif, 
has a higher apparent aJBfinity for P2 (Km = 0.26 pM) than does one of P2’s natural substrates, 
adenosine (Km = 0.92 pM) (de Koning 2001a). This could indicate a structural preference for 
the benzamidine group in P2 interactions. If this were the case then fiiture compounds would 
benefit from carrying a benzamidine in place of a melamine.
Some support for this idea comes jfiom the nitrofuran and nitroimidazole compounds. The 
benzamidine compounds 854 and 855 show higher apparent affinities than the melamine 
compounds 744, 745 and 719. This has to be interpreted with caution, however, as the active 
groups on these compounds are not comparable, the benzamidines carrying imidiazole groups 
and the melamines carrying furan groups.
Moreover, the in vitro toxicity experiments involving the TbATl and P2 transport deficient 
ATbatl cells reveal no difference in toxicity for these compounds towards either cell line, 
suggesting that the P2 transporter is not critical in the delivery of these compounds. It is 
possible that these compounds can be carried into the cell via diffiision. Both the HIV gpl20 
binding mimetics and nitroheterocylic compounds carry very lipophilic residues, which could 
aid in their passing across the cell membrane. If this is the case, then active transport is indeed 
unnecessary for uptake. Furthermore, other nitroheterocylces such as Megazol (Barrett et al.
2000) and Nifiirtimox (Tsuhako et al. 1991) have been shown to enter tiypanosomatid cells by 
diffusion.
More evidence for the redundancy of the P2 transporter comes from 748 and 749, which lack 
the P2 recognition motif altogether and consist solely of the nitrofuran portion of 744 and 745. 
They had extremely little, or no affinity, for P2 whatsoever, but they exhibit toxicities 
comparable to 744 and 745 in vitro. The very slight interaction of 748 with P2 (K, = 404 jliM) 
might be due to an interaction with the non-melamine amine group on this compound. The
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activity of 746 and 747 may also have been affected in some way by the presence of this 
amine.
The melamine bearing compounds described here have greater affinities for P2 when the 
melamine amines were monomethylated, as do the polyamine analogues in the previous 
chapter. This may be related to the methyl substitution increasing the electron density in the 
compound’s tc-system, which could potentially increase the contribution of %-stacking to the 
binding of the compound to P2. In the case of 746 and 747, which represent the carrier portion 
only, the reverse seems to apply, i.e. the presence of methyl groups diminishes apparent 
affinity. Other than the possible involvement of the non-melamine amine, no reason for this 
unexpected behaviour presents itself.
The in vitro toxicity experiments clearly show that the nitrofurans are much more toxic to 
trypanosomes than the nitroimidazoles. As mentioned earlier, the activity of these compounds 
relies on their nitro group being reduced to an active nitro anion radical. This is in turn related 
to the reduction potential of their nitro groups. The lower their redox potential, the less likely 
they are to be reduced. In general, nitrofiirans are more easily reduced than nitroimidazoles 
(Tocher 1997). Anaerobic cells have a lower redox potential than aerobic cells, vhich 
contributes to the generally greater toxicity of nitroimidazoles for anaerobic cells. As 
nitrofurans are more easily reduced than nitroimidazoles, their different redox potentials could 
also explain the differences in their respective toxicities. African trypanosomes are generally 
considered to be obligate aerobes, and therefore less able to reduce nitro imidazoles. The 
efficacy of nitroimidazoles such as Megazol is likely to be due to the presence of a specific 
enzyme -  possessing Megazol-reductase activity -  rather than a highly reductive intracellular 
environment.
The compounds 744 and 745 were tested in vivo, the only structural difference between 744 
and 745 being the monomethylated melamine amines present on 745. This difference is 
sufficient to lead to 745 being inactive in vivo up to the highest concentration used (40 mg/kg), 
and 744 being able to clear infection for up to 40 days in one of the animals in the study. The 
in vitro evidence seems to indicate that the melamine groups are not involved in the toxic 
nature of these compounds, but in vivo they must have some effect, whether that is in uptake
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or in interactions with intracellular targets. Reto Brun at the Swiss Tropical Institute, Brunei, 
is taking this promising result further with in vivo trials against both acute and chronic 
trypanosome infections in mice.
Difficulties may arise in any future development of these nitroheterocyclic compounds for 
clinical use due to mutagenic and carcinogenic properties. Many nitroheterocycles give a 
positive Ames test, including Megazol (Ferreira & Ferreira 1986), the development of which 
has been halted for this reason (Poli et al. 2002). Nitrofiiran compounds are, if anything, likely 
to be even more mutagenic as they are more easily reduced to form active metabolites. 
Nevertheless, 744 shows promise as a tiypanocide, and could be a useful lead compound. 
Further work is needed on this compound to assess its mode of action and its usefulness as a 
trypanocidal drug in vivo.
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Chapter V. Tlie Molecular Basis o f  Drug Resistance in Trypanosoma equiperdim .
5.1 Introduction
Although the P2 transporter may have some use as a carrier of trypanotoxic compounds, the 
loss of this transporter has been linked with drug resistance in both laboratory derived drug 
resistant strains and field isolates (Brun et al. 2001). hi order to fiirther investigate the role of 
P2 in drug resistance, the molecular basis fiir the development of drug resistance in a 
diamidine resistant strain of T. equiperdum with a much reduced P2-like adenosine transport 
component has been investigated. Because of the residual adenine sensitive, adenosine 
transport (P2-like) activity in this strain, it seemed likely that the change in P2 activity was 
due to a loss in affinity for the drugs as substrates, rather than a loss in P2 function (Barrett et 
al.l995).
5.1.1 TrvDanosoma eauiperdum
The trypanosomatid. Trypanosoma equiperdum infects equines causing a condition known as 
Dourine (Stephen 1986). The most notable feature of T equiperdum is its inability to be 
transmitted via an insect vector, instead the parasite is transmitted during coitus. This tissue 
parasite then localises to the capillaries of the mucous membranes in the urogenital tract and is 
transferred via these membranes or in seminal fluid during sexual intercourse. Trypanosomes 
do occasionally appear in the bloodstream of an infected host in chronic infections, which 
could result in mechanical transfer by a bloodsucking insect moving rapidly between hosts, 
but this is considered a rare event (Stephen 1986).
Infection with T. equiperdum results in a range of clinical symptoms. Early infection is 
characterised by oedema of the genital organs and a swelling of the lower abdomen. More 
established infections are generally linked with fever, anaemia, weight loss and the 
development of neurological symptoms. A typical feature of infection is the development of 
plaques in the skin. Although many of these symptoms may occur in any infected animal they 
are not progressive in their order of appearance, and some may not occur at all (Stephen 
1986).
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Infections with T. equiperdum share many symptoms with the closely related blood parasite 
Trypanosoma evansi. Positive diagnosis therefore relies upon the identification of parasites in 
the oedematous fluids of an infected animal. Trypanosomes can be few and fer between, even 
in these tissues, so diagnosis often relies upon indirect methods such as immunosorbent assays 
(Alemu et al. 1997) or DNA probes (Zhang & Baltz 1994). Treatment can be delivered in the 
form of suramin, berenil or cymelarsan (Brun et al. 1998), however clinical trials documenting 
efficacy have not been conducted, and the treatment of stallions and brood mares with 
available compounds is not recommended (Stephen 1986).
The incidence of Dourine is difficult to determine due to the lack of veterinary resources in 
endemic areas. However due to its lack of reliance upon an insect vector and climatic 
conditions it has a very wide distribution. Historically the disease is thought to have originated 
in Africa and to have spread with animal movements to become endemic in most of Europe. 
From here the disease spread east and was carried across to the Americas. Dourine was a 
disease of great concern over all of North America at the turn of the 20th century. It was 
eradicated from Canada in the 1920’s but persisted in the U.S.A. until 1949. Dourine is 
currently found in Afiica, Asia, Eastern Europe and South and Central America (Stephen 
1986).
Phylogenetically T equiperdum was thought to have originated from the mechanically 
transmitted parasite T evansi. Although both species are related to T. brucei, they are more 
closely related to each other. T equiperdum was thought to have descended from T, evansi 
because of its more specialised method of transmission and smaller host range (equines only 
as opposed to equines, camels, buffalo, cattle and deer in T. evansi infections) (Brun et al. 
1998). Molecular data in the form of isoenzyme analysis (Lun et al. 1992a) and RFLP analysis 
of kinetoplast DNA as well as genes for ribosomal RNA and variant surface glycoproteins 
(Lun et al. 1992b), supports the idea that the two are the same species.
Recently, however it has been suggested that in feet T, evansi is derived from T equiperdum. 
This theory is based on the presence of maxicircles in the kinetoplast DNA of T. equiperdum 
(Frasch et al. 1980; Riou & Saucier 1979) vriiich are absent in T. evansi (Borst et al. 1987). As 
it seems unlikely that T equiperdum could have re-acquired maxicircles, it has been proposed
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that T. evansi arose from a T. equiperdum cell that had lost its maxicircles and acquired the 
ability to reside in the general bloodstream allowing mechanical transmission (Lun et al. 
1992b).
5.1.2 TrvDanosoma equiperdum BoTat 1
5.1.2.1 Selection for Drug Resistance
T. equiperdum BoTat 1 (Bordeaux trypanozoon antigenic type 1), here referred to as T. 
equiperdum P originated from a stock held at the Pasteur Institute, Paris. A berenil resistant 
line, r. equiperdum PBR was derived from T, equiperdum P by serial passage through mice 
treated with increasing sub-curative doses of berenil (Zhang et al. 1993).
T. equiperdum PBR is 35.6-foid less sensitive to berenil and 4-fold less sensitive to 
cymelarsan than the sensitive line in vitro. The resistant line is also insensitive to berenil up to 
the maximum tolerated dose in Swiss mice and 4-fold less sensitive to cymelarsan in vivo 
(Table 5.1).
Cell Line
in vitro ( MECioo) in vivo (CDioo)
Berenil
(pg/ml)
Cymelarsan
(pg/ml)
Berenil
(mg/kg)
Cymelarsan
(mg/kg)
T equiperdum P 0.0556 0.005 18 0.5
T equiperdum PBR 1.78 0.02 >89 2
Table 5.1. Drug sensitivities of T equiperdum P and PBR (Zhang et al. 19931.
MEC 100 =  Minimal effective concentration which killed 100% o f trypanosomes during 24 hours o f  drug 
exposure.
CD 100 = Curative dosage in 100% o f  mice.
5.1.2.2 PI and P2 Adenosine Transport in T. equiperdum P and PBR
The P2 purine nucleoside transporter has been shown to be important for the transport of 
melaminophenyl arsenicals and diamidines in trypanosomes (Carter & Fairlamb 1993). Its loss 
of ftmction through loss or mutation of TbATl confers resistance to these drugs (for a full
80
Chapter V. The Molecuiar Basis o f  Drug Resistance in Trypanosoma equiperdum.
discussion see Chapter I). Barrett et al. investigated the role that this transporter plays in the 
resistance of 71 equiperdum PER to trypanocidal drugs (Barrett et al. 1995).
The sensitive strain, T. equiperdum P, had a typical P1/P2 adenosine transport system. The PI 
component was found to have an apparent Km of 0.6 pM and a Vmax of 8.4 pmol/s/10^ cells for 
adenosine. The P2 component had an apparent Km of 0.7 pM and a Vmax of 6.9 pmol/s/10® 
cells. This accounts for all measurable adenosine uptake into these cells.
In 71 equiperdum PER the overall rate of adenosine uptake was reduced. The PI transport 
component has a Km of 0.66 pM and a Vmax of 4.15 pmol/s/10® cells, making it comparable to 
that in 71 equiperdum P although with a slightly reduced Vmax. After blocking PI with excess 
inosine, a P2-like adenosine transport component, which could be inhibited by the addition of 
excess adenine, was apparent. However, apparent Km and Vmax values could not be determined 
for this component.
Because of this residual P2-like activity, it was postulated that the change in P2 activity was 
due to a loss in affinity for the drugs as substrates. Drug resistance was acquired very quickly 
(T., Baltz, personal communication) suggesting that any change might have come about by the 
appearance of one or more point mutations in the TbATl gene. This mechanism of drug 
resistance, where point mutations to a transporter have altered the substrate specificity and 
conferred drug resistance, has been reported in Leishmania donovani (Vasuvedan et al. 2001),
5.2 Results
5.2.1 Rapid Fluorescence Test for Drug Resistance
As described in Chapter VI, the diamidine compounds DB 75 (2,5-bis (4-amidinophenyl) 
furan) and DB 544 (2,5-bis (4-amidinophenyl) 2,3-bis methylfuran) enter trypanosomes via 
the P2 transporter and fluoresce when bound to DNA. The absence of this transporter on a cell 
surface results in a delay in the development of fluorescence within a cell. 71 equiperdum P 
and PER were tested for their ability to internalise these fluorescent compounds. The time
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taken for fluorescence to develop is shown below, in Table 5.2 and a comparison of 
fluorescence at 10 minutes in Figure 5.1.
Incubation time 
(min)
DB751llOpM) DB 544 (10 pM)
P PBR P PBR
0 + - + -
1 + - + -
2 + - + -
5 + - + -
10 + - + -
Table 5.2. Development of fluorescence, at room temperature, in the presence of 10 pM DB 
75/DB 544.
- : no fluorescence 
+ : fluorescence
T. equiperdum P T. equiperdum PBR
Figure 5.1. Development of fluorescence from DB 75 in 71 equiperdum P and PBR cell lines 
after 10 minutes.
Fluorescence is clearly visible in the P cell line, but has not yet developed in the PBR cell line. Magnification is 
lOOx, bars are 10 pm.
The lack of fluorescence developing in the PBR cell line indicates the lack of a typical P2 
transport component capable of associating and internalising these diamidines.
5.2.2 Sequencing of Tequiperdum P and T, equiperdum PBR TbATl
Figure 5.1 indicates that the P2 transporter is not functional in 71 equiperdum PBR, Wiich 
contradicts the original hypothesis of a P2 transporter carrying point mutations affecting
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substrate affinity. It was therefore decided to compare TbATl from both the P and PBR cell 
lines.
The entire TbATl ORF (1389 bp) and short flanking regions (PCR product size -1500 bp) 
were amplified, and 10 independent PCR products sequenced from each cell line in order to 
identify and confirm the presence of any point mutations in the sequence. DNA for sequencing 
was extracted from cells grown in mice that had either been challenged with berenil in vivo at 
20 mg/kg and survived exposure {T equiperdum PBR), or had been shown to be fix)m 
infections that could be successfiilly treated with berenil at 20 mg/kg (71 equiperdum P).
5.2.2.1 PCR of TbATl
PCR was conducted using the primers P2F and P2R, both of which fall outwith the open 
reading fi-ame (ORF) of TbATl, Figure 52. All PCR reactions were conducted in the presence 
of Pfu polymerase in order to minimise the risk of introducing point mutations into the 
sequence. PCR product, once purified was cloned in the PGEM-T vector and sequenced. Both 
strands were fully sequenced in all cases, using internal primers to give complete coverage of 
the gene.
5’ ^  gg TbATl ORF D ^^ 2 R
P2F : CAT GCG CTT TGG TGG AGG
P2R : TTG GCG AAT CGG TGT ACG
Figure 5.2. TbATl open reading fi-ame and primers used for amplification. 
PCR product from this reaction was approximately 1500 bp in length.
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5.2.2.2 Sequences
Sequencing indicated that all of the 71 equiperdum PBR clones have identical sequence, 
varying from that of 71 brucei 927 by 6 nucleotide point mutations resulting in 2 changes at 
the amino acid level. The 71 equiperdum P sequences were slightly more ambiguous, resulting 
in 3 different patterns of point mutations, and 3 patterns of amino acid changes. Table 5.3.
On closer examination of the 71 equiperdum P sequence data, there appeared to be two main 
patterns. One carries adenosine residues at positions 151 and 627 (‘a’ allele, clones P6, P8 and 
P9), which is identical to 71 brucei 927 strain and the drug resistant PBR cell line. The other 
pattern, as seen in clones P I-5, P7 and PIO, has cytosine residues at these positions (‘c’ allele). 
The cytosine point mutation at position 151 results in an amino acid change from a lysine to a 
glutamine.
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Clone PIO, altiiough conforming to the second pattern (‘c’ allele, a cytosine at positions 151 
and 627) has an additional point mutation, not identified in any other sequence, of an 
adenosine at position 205 instead of a guanosine (Table 5.3). PIO was not re-sequenced, due 
to time constraints, but, although both strands were sequenced, the likelihood remains that the 
extra mutation at position 205 in the ORF is an error caused by misincorporation during PCR 
amplification. A revised table of nucleotide point mutations, that ignores the point mutations 
common to all T. equiperdum clones, P and PBR is shown below. Table 5.4.
1u z 2 cu 2 cu S
r-cu ooCu 2 oCu i I I I I I 1i I 01
1151 c c C c c A C A A C A A A A A A A A A A205 G G G G G G G G G A G G G G G G G G G G627 C C C C C A C A A C A A A A A A A A A A
Table 5.4. Revised table of nucleotide point mutations.
This table ignores any point mutations common to all T. equiperdum  clones. The mutation at 205 in PIG is likely 
to be a sequencing error (see text).
From the sequencing data it appears that T. equiperdum P i s a  heterozygote for TbATl 
carrying both the ‘a’ and ‘c’ alleles, while PBR has lost heterozygosity and is homozygous at 
this locus containing only the ‘a’ allele. This has been investigated fiirther by Southern blot.
5 2 3  Southern Blot
The restriction enzymes Bfal and BssSlcut specifically at position 627 within the TbATl gene. 
Bfal cuts where there is an adenosine residue at this position (‘a’ allele) and BssSI Wiere there 
is a cytosine residue (‘c’ allele). Figure 5.3. A Southern restriction digest at this site should be 
diagnostic for the two putative alleles identified through sequencing.
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BssSI Bfal EcoRl 
\  \  \
Bfal S’ .C’ TA GTG..3’ 3 ’..G A T .C A C  5'
- X -
Bfal BssSI \  \
* / /  -2 ,0 0 0  bp -7 .0 0 0  bp
‘a’ allele, adenosine at position 627.
VA
BfaEcoRl
\ \
BssSI 5 .C’ TCGT G ..3’ 3 .G A G C A .C  5' Bfal BssSI \  \
-2 ,0 0 0  bp -7 ,0 0 0  bp
c' allele, cytosine at position 627.
Figure 5.3. Restriction enzyme sites in TbATl.
The blue bar represents the ORF and restriction sites are in orange. The restriction sequences for B fal and BssSI 
are shown, with the sequence differences between the two highlighted in red. The approximate size o f  the 
fragments are, A = 10 kb, B = 878 bp, C = 10 kb, D = 4.1 kb, E and F either 9.5 kb or 1.7 kb.
The results of a digestion of genomic DNA with these enzymes and EcoRI are shown in 
Figure 5.4.
a) b) T  n ^u ip frd u mp PBR P PBR
^  i -  5 1 ^  i ^  ^t i l g ,  1  110 kb — I
6 kb —  
5 kb —  
4 kb —
2 kb —
750 bp —
m ^
Figure 5.4. Southern Blot of T equiperdum P and PBR DNA.
Genomic D N A  was digested witfi B fal, BssSI and EcoRl. The Blot was probed with the TbATl ORF. Blot a) is a 
2 day exposure, b) is a 2 week exposure o f  the same blot, showing the presence o f  the 2 kb band in the E coR l 
digest o f  r. equiperdum  P.
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As predicted, the Bfal digests, which cut within the ‘a’ allele only, produce a band of around 
900 bp and another, much larger at -10,000 bp in both P and PBR digests. One other band, of 
a different size for either sample was identified for each digest. The T. equiperdum P digest 
produced a band of around 4,100 bp. This is likely to be due to an unidentified ^ /re s tr ic tio n  
site upstream of the ‘c’ allele, closer to the open reading fi-ame than the upstream restriction 
site in the ‘a’ allele. The PBR cell line lacks this allele and hence the digest product. The PBR 
cell line Bfal digest has a fiiint band at approximately 2,000 bp. The significance of this extra 
band is uncertain. However, it could be kinetoplast DNA, which can fi^quently be seen in 
Southern restriction digests carried out with a large quantity of genomic DNA, and runs out at 
approximately 2,000 bp.
The BssSI digests, wfiich cut within the ‘c’ allele, produce three bands in the P cell line, 
indicating the presence of two alleles. The PBR cell line digests has only a single band, 
indicating that this enzyme did not cut the PBR TbATl ORF at all. This points towards the 
absence of the ‘c’ allele as predicted fi-om the sequences obtained for PBR.
The EcoRl digest produced a band of around 6,000-7,000 bp in both strains. Both cell lines 
also have a very weak band at around 2,000 bp. This is likely to be an upstream restriction 
digest product, which contains a 27 bp firagment of the ORF with which the blots were probed.
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5.2.4 Northern Blot
RNA isolated fiom T. equiperum P and PBR cell lines, blotted and probed with TbATl (entire 
ORF) indicates that PBR lacks TbATl transcript (Figure 5.5), while a 2.3 kb transcript 
corresponding to this gene is apparent in T equiperdum P.
TbATl O R F T I M
9.5 kb.
7.5 kb"
4.4 kb.
2.4 kb.
1.4 kb.
0.24 kb.
P B R  P  P B R
Figure 5.5. Norüiem Blot of T. equiperdum P and PBR.
Blots were probed with the TbATl ORF and subsequently with a control probe for Triosephosphate isomerase 
(TIM), in order to confirm the presence o f  RNA in both the P and PBR lanes.
52.5 P2 Substrate Uptake Assays
Barrett et al found that in T equiperdum PBR the overall rate of adenosine uptake is reduced. 
The PI transport component was slightly less Wiile a P2-like adenosine transport component, 
which could be inhibited by the addition of excess adenine, was apparent. However, this later 
component was of low activity and Km and Vmax values could not be determined (Barrett et al. 
1995).
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Because of this residual P2-like activity, it was postulated that the change in P2 activity was 
due to a loss of affinity for the drugs as substrate molecules. The results presented above, 
however, indicate a lack of any fimctional P2 transporter on the surfece of T. equiperdum due 
to loss of transcription of this gene. In order to investigate this further, uptake assays were 
carried out with radiolabelled diminazene aceturate (berenil), previously shown to enter the 
cell solely through the P2 transporter (H. de Koning, unpublished data). Uptake of 20 pM 
berenil over time in both T. equiperdum cell lines is shown in Figure 5.6.
120
T. equiperdum P 
T. equiperdum PBR100
I
600200 400 
Time (s)
Figure 5.6. Uptake of berenil in T. equiperdum P and PBR.
Uptake o f 20 pM berenil overtim e. Bars indicate standard deviations, n = 3.
The results indicate that berenil uptake in T. equiperdum PBR is very much reduced. The 
residual uptake may indicate the presence of another low affinity transporter, or it may be due 
to ^H-berenil caught in the intercellular space during the experiment.
Since a residual adenine-inhibitable adenosine uptake component had been identified in PBR 
previously, yet Northern blot data indicated a functional loss of TbATlfVl^ the question 
remained as to the identity of this residual adenine-sensitive adenosine uptake component. 
Recent research has identified another trypanosome transporter that can convey adenosine 
with a low affinity. The TbNBTl transporter has a high affinity for hypoxanthine (Km= 0.66 
pM), and a low affinity for adenosine (Ki = 1900 pM,), as measured when expressed in yeast
90
Chapter V. The Molecular Basis o f  Drug Resistance in Trypanosoma equiperdum
(H. de Koning, unpublished data). It was possible that the residual adenosine uptake in T. 
equiperdum PBR was due to the action of this transporter. In order to investigate this the 
uptake of 10 pM adenosine was followed in the presence of various inhibitors. 1 mM 
inosine was used to block PI specific transport, 1 mM adenine to block P2 transport and 1 mM 
hypoxanthine to block TbNBTl transport of adenosine. The results are shown in Figures 5.7 
and 5.8.
Figure 5.8Figure 5.7 800800
600600
2  4002  400
^  200^  200
400 600200400 600200
_ T. equiperdum P jr . equiperdum PBR
Time (s) Time (s)
No inhibitor
1 mM inosine
1 mM inosine and 
hypoxanthine
1 mM inosine and 
adenine
1 mM inosine, adenine 
and hypoxanthine
Figures 5.7 and 5.8. Inhibition of adenosine uptake in T. equiperdum P and PBR.
Uptake o f  10 pM adenosine over time. Bars indicate standard deviations, n = 3.
The above experiments were also carried out on a ATbatl cell line that lacks any P2 transport 
lunction (see Chapter VI for details). The results are shown in Figures 5.9, 5.10 and 5.11.
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6 OO1
TbATl
ATbatl
400
§ 200
Time (s) 600
Figure 5.9. Uptake of berenil in TbATl and ATbatl.
Uptake o f  20 |iM  berenil over time. Bars indicate standard deviations, n = 3.
Figure 5.10 Figure 5.11
1000 1000TbATl ■ ATbatl
800
600o
o 400 
200
800
^  6000Z
1 200
400
200 400 
Time (s)
600200 600400 
Time (s)
No inhibitor 
1 mM inosine
1 mM inosine and 
hypoxanthine
1 mM inosine and 
adenine
1 mM inosine, adenine 
and hypoxanthine
Figures 5.10 and 5.11. Inhibition of adenosine uptake in TbATl and ATbatl. 
Uptake of 10 pM adenosine over time. Bars indicate standard deviations, n = 3.
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Adenine inhibitable uptake of adenosine was identified in the ATbatl cell line as well as the 
PBR cell line. This result indicates the presence of an additional system capable of 
adenine/adenosine uptake in T brucei and T. equiperdum, independent of TbATl. Since 
previous studies revealed a Km for adenosine could not be measured for this transporter, it 
indicates a low afiSnity for this nucleoside. The transporter is not TbNBTl, as hypoxanthine 
does not inhibit this adenosine uptake. However, it is probably encoded by one or more of the 
plethora of other nucleoside/nucleobase transporter genes in the T. brucei genome.
5,3 Discussion
TbATl in the T equiperdum P cell line dififers fi-om that of T brucei 927 by six nucleotide 
point mutations resulting in two changes at the amino acid level. Two further point mutations, 
one of which results in an ammo acid change, are seen in seven of the clones (‘c’ allele), the 
other three having sequence identical, at that point, to T. brucei 927 (‘a’ allele). The T. 
equiperdum PBR cell lines were all identical, having the same sequence as the three T. 
equiperdum P ‘a’ allele clones.
Of the six mutations seen in all clones, three of these mutations have also been characterised 
in STIB 777R, a laboratory derived melarsen oxide-resistant cell line (Maser et al. 1999). Two 
of these mutations code for changes in the amino acid sequence of TbATl, and one is a silent 
mutation. These same three mutations also occur, among others, in T. b. gambiense CSF 
isolates firom patients in Uganda, in a T. b. rhodesiense isolate (STIB 871) that shows some 
resistance to berenil and melarsoprol, and in a 21 6. gambiense stock (K 003) from Angola 
(Mato vu et al. 2001b). Figure 5.12 shows a cartoon of relative position of the mutations in the 
TbATl ORF in T. brucei 927, including those that appear to be conserved between stocks.
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00
TbATl
ORF
T625C A716G  
A627C
A151C
T. equi. P 
T. equi. PBR 
CSF Isolates 
STIB 871 
K 003
X X
COOH
NHj \J Cytopli
Figure 5.12. Position of mutations in T. equiperdum TbATl.
The blue bar represents the TbATl ORF as described in T. brucei 927. Mutations for which T. equiperdum  
appears to be heterozygous are shaded red and white, those that were present in all clones are in block red colour. 
The positions o f  changes in amino acid sequence between T. equiperdum  and T. brucei are represented as red 
dots on the cartoon o f  predicted protein structure (insert). T. equiperdum, STIB 871, K 003 and the CSF isolates 
all have identical mutations at the positions indicated by a cross.
The amino acid change K51Q is predicted to occur on the first extracellular loop, and 
represents a change fiom a positively charged hydrophilic residue to a neutral polar residue. 
G181E is predicted to occur on the extracellular face of the transporter, and represents a 
change to a charged residue with a bulky side chain. D239G is predicted to occur on the large 
intracellular loop, and represents a change to a residue with a similar polar character, but 
carrying a less bulky side chain (Figure 5.12).
Further to the mutations in TbATl illustrated above, the CSF isolates, STIB 871 and K003 also 
share one more mutation among themselves and a further five point mutations with STIB 
777R (see Chuter I). Why there should be such conserved mutation ‘hotspots’ among isolates 
differing in species and location is subject to speculation.
The sequencing results indicate that TbATl in T. equiperdum P exists as two alleles. The drug 
resistant T equiperdum PBR cell line however, only appears to have the ‘a’ allele, with an 
adenosine at positions 151 and 627. This apparent loss of heterozygosity may account for the 
lack of P2 transcript and hence the loss of P2 function in T equiperdum PBR. If the ‘a’ allele
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in the P cell line, as sequenced in clones P6, P8 and P9, were to be transcriptionally silent or 
produce a non-functional transporter, drug resistance could then have come about by a loss of 
heterozygosity in the PBR line. However, the ‘a’ allele contains a sequence that is identical, at 
postions 151 and 627 of the ORF, to TbATl from both T brucei 427 and 927 wild type strains, 
which have fully fimctional P2 transport systems and a typical sensitivity to drugs. This would 
suggest that these mutations are unlikely to be instrumental in bringing about drug resistance.
Another possibility is that a silent copy of TbATl has been created due to changes up or 
downstream of the open reading frame that regulate the expression of the ‘a’ allele. In this 
model, a mutation occurring at one allele (the ‘a’ allele) might silence that gene and then loss 
of heterozygosity would lead to silencing of the TbATl locus. In the PBR cell line, it would 
appear that the active ‘c’ allele has been selected against, and a subsequent loss of 
heterozygosity has resulted in a loss of expression of the TbATl gene. A loss of expression of 
TbATl has been identified previously in T b. gambiense 386 mr, another drug resistant cell 
line that has an unchanged TbATl ORF from its parent cell line T b. gambiense 386 (R. 
Burchmore, personal communication). Loss of heterozygosity may come about through the 
replacement of the active allele with the inactive one, or through the loss of one copy of the 
gene.
A loss of expression of TbATl would be expected to effectively eliminate all P2 transport 
function in a cell line. However, a P2-like, adenine sensitive adenosine transport component 
was identified in the resistant cell line (Barrett et al. 1995) which had led to the original 
hypothesis that drug resistance had arisen jfrom a change in affinity of the transporter for the 
substrate. Berenil, a commonly used diamidine drug is taken up solely through the P2 
transporter (H. de Koning, unpublished data). Uptake assays in which berenil uptake is lost in 
T. equiperdum PBR (Figure 5.6) help verify a loss of P2 transport that a loss of expression 
suggests.
Blocking the uptake of adenosine with inosine and subsequently adenine shows that there still 
is an adenine sensitive adenosine transport component in the T. equiperdum PBR cell line 
(Figure 5.8). This was also identifiable in the ATbatl knock out cell line that has been 
confirmed to have no P2 transport activity (Figure 5.11). The adenosine uptake could be due
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to the presence of an as yet unidentified adenosine transporter on the cell surface, one which 
could also interact with arsenical trypanocides. The TbNBTl hypoxanthine transporter was 
identified as a possible candidate, but ruled out, as blocking its activity with an excess of 
hypoxanthine had no effect on the remaining adenosine uptake. This additional, low affinity 
adenosine uptake component could correspond to the third adenosine uptake component 
(adenine sensitive, berenil insensitive) previously reported in T. evansi (Ross & Bams 1996).
The loss of P2 function has been related to resistance to the melaminophenyl arsenicals and 
the diamidine classes of trypanocidal compounds. Table 5.5, below, shows the in vitro 
susceptibility to berenil and cymelarsan of T. equiperdum P and PBR lines, and the ATbatl 
cell line and its wild type parent.
Drug IC50 Resistance
Factor
IC50 Resistance
FactorT
equiperdum
P
T
equiperdum
PBR
TbATl ATbatl
Berenil
(|xg/ml)
0.0556 1.75 31.5 0.124 2.32 19
Cymelarsan
(jLtg/ml)
0.005 0.02 4 0.0061 0.0124 2
Table 5.5. Resistance of T equiperdum P and PBR and TbATl and ATbatl cell lines to berenil 
and cvmelarsan.
Resistance to berenil in both T. equiperdum PBR and ATbatl is high, 31.5-fold and 19-fold 
respectively. As berenil has been shown to access the hypanosome cell solely through the P2 
transporter, the absence of this transporter in these cell lines would induce a high resistance 
factor. The relatively low resistance fector (4 and 2-fold) that both show to cymelarsan was 
unexpected. Cell lines that have been selected under laboratory conditions for resistance to 
arsenicals typically show very high levels of resistance, for example T b. brucei 247 mr has a 
resistance factor of greater that 130-fold as compared to its parent cell line (Scott et al. 1996).
The results of the toxicity tests show that the loss of P2 alone does not account for these high 
resistance levels. Arsenical compounds could have another route of entry into the cells, and a
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loss of this transport activity could lead to a higher level of resistance. Alternatively, the high 
levels of resistance seen in laboratory derived strains could be due to a series of changes in the 
target cell, brought about by the practice of constant selection under sub-curative doses of 
arsenical. The loss of fimction of P2 however, appears to be a conserved feature of drug 
resistance in many cell lines, and under dmg pressure, could be one of those most readily 
induced.
The two- or four-fold difference in susceptibility to arsenicals that the loss of P2 brings about 
becomes veiy important when considering the pharmacokinetics of arsenicals in the CNS of 
infected patients. Arsenicals are present m the CNS at levels veiy close to the I C 5 0  value of the 
drug. Even a two-fold loss in susceptibility could result in drug tolerant cells that could 
survive treatment within the CNS and cause relapse.
There remain many other genes that could potentially code for membrane bound nutrient 
transporters, including nucleoside and nucleobase transporters. The substrate recognition 
motife for these transporters remain to be described, but they could possibly account for the 
adenine sensitive adenosine uptake seen in these P2 deficient cell lines.
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6.1 Introduction
The current resurgence of Human African Trypanosomiasis (HAT), coupled with an increased 
incidence of drug resistance, is of great concern to health officials in affected areas (Barrett 
1999). Relapse rates of 20 to 30% have been reported for treatment with melarsoprol, the 
principal dmg of use against late stage infection (Brun et al. 2001). The only available 
alternative to melarsoprol treatment in arsenical-refractory infections is 
Difluoromethylomithine (DFMO). However, despite its efficacy against T. b. gambiense 
infection, DFMO is restricted in use due to high costs of administration and a limited supply 
(Etchegory et al, 2001). A quick, simple and sensitive clinical test capable of identifying drug 
resistant strains would allow health workers to decide on which course of treatment is most 
appropriate for each patient without having to wait for clinical relapse prior to making a 
choice.
The work presented here demonstrates a simple and effective assay that can distinguish 
between laboratory derived strains of parasite susceptible or resistant to treatment with 
commonly used trypanocidal compounds. The test has been developed using dicationic 
compounds that fluoresce when associated with DNA. These compounds also carry the 
recognition motif for the P2 purine transporter (Figure 6.1), the loss of which is closely 
associated with resistance to arsenical and some diamidine trypanocides (Barrett & Fairlamb 
1999). It was anticipated that these compounds would be carried into the cell via the P2 
transporter and the level of fluorescence achieved in live cells over a short period of 
incubation could distinguish between strains of parasite that are susceptible or resistant to 
treatment with commonly used trypanocidal compounds. This test may form the basis of an 
assay capable of detecting drug resistant trypanosome infections in both humans and cattle in 
the field.
6.1.1 Fluorescent Aromatic Dications
The aromatic dicationic compound pentamidine (Figure 6.1) has been used for over 60 years 
as a treatment for HAT (Wang 1995), being effective against early stage trypanosomiasis, 
when the parasites are in the bloodstream. It cannot cross the blood brain barrier in sufficient
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quantities to clear trypanosomes that have established within the central nervous system, 
although it has been proposed to have some effect in the ‘early late stage’ of the disease (Doua 
et al. 1996). Pentamidine can also produce a range of side effects such as hypotension and 
renal and hepatic toxicity, and is inactive Wien administered orally due to poor gastrointestinal 
absorption.
NH
Pentamidine DAPI
,CH
NH
NHDB75 DB544NHNH NHNH
DB289
OMeMeO
Figure 6.1. Chemical structures of pentamidine and analogues.
P2 recognition motife are shown in red.
Despite these drawbacks, interest in pentamidine has increased due to its use as a secondary 
drug against AIDS related Pneumocystis carinii pneumonia (Smith & Gazzard 1991), 
Analogues have been developed in an effort to reduce undesirable side effects and to broaden 
the range of pathogens that can be treated.
A diphenylfiiran, 2,5-bis (4-amidinophenyl) fiiran (DB 75, Figure 6.1) was found to be 
effective against many microbial pathogens when administered intravenously. When 
administered orally, however, DB 75 was only able to clear the intestinal parasite 
Cryptosporidium parvum (R. Tidwell, personal communication) among the pathogens tested. 
DB 75, like pentamidine, was found to be poorly absorbed across the gastrointestinal
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epithelium. Further studies with analogues resulted in the synthesis of a range of aromatic 
diamidinoximes and other pro-drugs, which can be readily absorbed across the gastro­
intestinal epithelium and are metabolised by the liver to their respective active dications,
DB 75 has already been shown to be active against trypanosomatids when administered 
parenterally (Das & Boykin 1977; Steck et al, 1981; Steck et al, 1982), but to only have veiy 
limited activity when administered orally. Further studies have shown that the dimethoxime of 
DB 75, 2,5-bis(4-amidinophenyl)fijran bis-D-methylamidoximine (DB 289, Figure 6.1), is 
converted on absorption (probably by the liver) to DB 75. DB 289 is effective on oral 
administration against different animal models of early stage trypanosomiasis, has 
successfully completed phase I clinical trials, and is entering phase IIA trials in Angola and 
DRC (Legros et al. 2002), DB 289 and DB 75 are still, however, unable to clear infections 
with CNS involvement as, like other diamidines, they are unable to cross the blood brain 
barrier in sufficient quantities to reach trypanocidal levels.
The therapeutic diamidines in Figure 6.1 have two features in common which have been 
exploited in the development of this assay. These are their ability to interact with the P2 
transporter and to fluoresce when bound to DNA, The ability of pentamidine and other 
diamidines to interact with the P2 transporter is due to the presence of the P2 recognition motif 
(de Koning 2001a) in the form of an amidine group at either end of the molecule. An ability to 
bind to DNA is common to many dicationic compounds and may be responsible, at least in 
part, for the antimicrobial action of these compounds (Wang 1995), Some of the novel 
dicationic compounds also fluoresce when bound to DNA, which makes their presence in 
cells, bound to the nucleus and the kinetoplast, easy to detect (Figure 6.2). This property is 
widely exploited in the case of 4’,6-Diamidino-2-phenylindole (DAPI, a fluorescent 
diamidine. Figure 6.1) which is used as a standard DNA stain for many cell types.
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Figure 6.2. Live bloodstream form trvpanosome stained brightlv with DB 544.
Fluorescent compound associates with the D N A  in the nucleus and the kinetoplast. This cell contained paired 
nuclei and kinetoplasts since it was in the process o f  division, prior to cytokinesis. Tw o flagella are also visible.
6.1.2 The Assay
A recent study from north western Uganda (Matovu et al. 2001a) has shown that T. b. 
gambiense isolated finm patients were less susceptible to melarsoprol in vitro than parasites 
previously isolated in other foci in West Africa (minimum inhibitory concentrations of 0.009 
to 0.072 fig/ml as opposed to 0.001 to 0.018 pg/ml). Within the study area, however, 
trypanosomes isolated from patients not responding to arsenical treatment are similar in 
sensitivity to arsenicals as those isolated from patients that responded to the drug.
It is possible that the overall slight decrease in susceptibility to arsenicals, coupled to host- 
related fectors (e.g. permeability of extravascular sites to arsenicals), are responsible for the 
increased incidence of treatment feilure in the study area. This seems more likely still when
1 0 2
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taking into account that the quantity of melarsoprol that accumulates in the CSF is close to the 
normal effective concentration of the drug against wild-type parasites, (Keiser & Burri 2000; 
Keiser et al. 2000b). Data is not available for other sites, but failure to accumulate drug to 
trypanocidal levels in given extravascular localities would lead to relapse. Matovu and 
CO workers were also able to show some correlation between mutations in TbATl (and 
presumably the loss of normal P2 transport function) and arsenical resistance.
The situation in the field regarding loss of P2 function and drug resistance remains ambiguous. 
However, the loss of P2 function is associated with arsenical resistance in all laboratory 
derived lines studied to date (R. Burchmore, personal communication), and is associated with 
a two-fold increase in resistance to arsenicals. Therefore a simple assay for P2 function, which 
could be used in a field situation, may be able to give an indication of resistance. This would 
allow health workers to prioritise patients with possible arsenical-refiactory infections for 
treatment with DFMO. Such a test may be possible if the compounds described above were to 
gain entry into the trypanosome solely or predominantly via the P2 transporter. Their 
exclusion from the cell (indicated by the lack of fluorescence) would indicate a loss of 
transporter fimction and an increased resistance to arsenical treatment in that cell line.
A number of fluorescent diamidines were used to test whether they could be used in such a 
test. Compounds included DAPI, and the compounds DB 75 (2,5-bis 4-amidinophenyl furan) 
and DB 544 (2,5-bis (4-amidinophenyl) 2,3-bis methylfiiran), two dicationic compounds 
known to fluoresce strongly when associated with DNA in the parasite. Figure 6.1.
6.1.3 Cell Lines Tested
6.1.3.1 TbATUATbatl
The ATbatl (P2) null mutant clone was constructed from T. b. brucei strain MiTat 1.2 
(BS221) {TbATl) cloned cell line, (Enock Matovu, unpublished data). The P2 knockout cells 
show a 2 to 2.5-fold higher resistance to arsenical compounds and to pentamidine, and 18.6- 
fold higher resistance to diminazene aceturate, the active component of berenil. These results 
were derived by Alamar Blue assay and are shown in Table 6.1.
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Tiypanocidal Compound TbATl I C 5 0  (pg/ml)
ATbatl I C 5 0  
(pg/ml)
Resistance
factor
Melarsen Oxide 0.0037 0.0107 2.89
Cymelarsan 0.0061 0.0124 2.02
Diminazene 0.124 2.32 18.68
Pentamidine 0.005 0.012 2.4
Table 6.1. Sensitivity o f TbATl and ATbatl cell lines.
Cell lines were tested against arsenicals and diamidines.
6.1.3.2 T equiperdum P/PBR
T equiperdum P and berenil resistant T equiperdum PBR. T. equiperdum PBR was selected in 
vivo for berenil resistance for which it is 36 times less sensitive. The PBR cell line is also 4- 
fold less sensitive to arsenicals, as shown in Table 6.2, (Zhang et al. 1992). Recent 
experiments (reported in Chapter V) have shown PBR to have an identical TbATl open 
reading frame to the P strain. The absence of RNA detectable by Northern blot suggests that 
the deficiency in P2 transport in this cell line may be due to a lack of transcription of the gene 
(reported in Chapter V).
Trypanocidal
compound
In vivo 
CDioo
activity
[mg/kg) Resistancefactor
In vitro activity 
MECioo (pg/ml) ResistancefactorP PBR P PBR
Diminazene 18 >89 >5 0.0556 1.78 32
Cymelarsan 0.5 2 4 0.005 0.02 4
Table 6.2. Sensitivitv of P and PBR cell lines, from Zhang. Z. 0.. 1992.
CD 100=  Curative dose in 100% o f  infected mice.
MECioo = Minimum effective concentration killing 100% o f  trypanosomes in 24 hours o f  exposure.
6.1.3.3 T b. bruceilAHlAl mr
The arsenical resistant T b. brucei 247 mr cell line was derived from the T. b. brucei 247 cell 
line. 247 mr was selected in vivo to increasing doses of cymelarsan. The resistant cell line is 
130-fold less sensitive to cymelarsan, (Scott et al. 1996), 16-fold less sensitive to berenil and 
over 63-fold less sensitive to pentamidine (Alan Scott, Ph.D. Thesis, University of Glasgow) 
in vivo (Table 6.3). The 247 mr cell line has been shown to lack the TbATl open reading frame
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altogether, resulting in a ‘natural knockout’ of P2 transport (R. Burclunore, personal 
communication).
Trypanocidal
compound
Minimum curative close in vivo, (mg/kg) Resistance factor247 247 mr
Cymelarsan 0.3 >40 >130
Diminazene 2 32 16
Pentamidine 1.6 >100 >63
Table 6.3. Sensitivitv o f247/247 mr cell lines.
6.1.3.4 T. b. gambiense 386/386 mr
The arsenical resistant T. b. gambiense 386 mr cell line was derived from the T. b. gambiense 
386 cell line. The resistant cell line was also selected in vivo with increasing concentrations of 
cymelarsan. 386 mr is 20-fold less sensitive to cymelarsan treatment, Table 6.4, (Scott et al. 
1996). Data for diamidines is not available. As with PBR, 386 mr has a full TbATl open 
reading frame, but lacks detectable transcript (R. Burchmore, personal communication).
Trypanocidal
compound
Minimum curative glose in vivo, (mg/kg) Resistance factor386 386 mr
Cymelarsan 2 >40 >20
Table 6.4. Sensitivitv o f386/386 mr cell lines. 
From Scott, A . G., 1996.
6.2 Results
6.2.1 Interaction of Aromatic Diamidines with Pentamidine Transporters
Pentamidine is known to enter trypanosomes through three separate transport systems (de 
Koning 2001b). P2 transports pentamidine with a Km of 0.26 pM and a Vmax of 0.068 
pmol/10^ cells/s. Two further pentamidine transporters have been identified in the 
trypanosome, the high affinity pentamidine transporter, HAPTl (Km = 0.036 pM, Vmax = 
0.0044 pmoI/10^ cells/s), and the low affinity pentamidine transporter, LAPTl (Km = 56.2 pM, 
Vmax = 0.85 pmol/10^ cells/s). HAPTl has a high affinity, but only a limited capacity for
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transporting pentamidine, which is reflected in its low V^ax value. This means, that at 
physiologically significant concentrations, P2 and LAPTl (with a low affinity but high 
capacity for transport) are the most important transporters with respect to the transport of 
pentamidine. Figure 1.10 shows the contribution that each transporter makes to uptake at any 
given pentamidine concentration.
Should the fluorescent analogues also be able to enter the cell via HAPTl and LAPTl, their 
ability to indicate the absence of P2 transport function would be compromised. It was 
therefore necessary to determine the ability of each diamidine to act as a substrate for each 
transporter.
Pentamidine, DAPI and the compounds DB 75 and DB 544 have previously been screened for 
their ability to inhibit transport of radiolabelled substrates of these three transporters. Affinity 
for P2 was measured by their ability to inhibit the uptake of adenosine, and inhibition of 
pentamidine uptake was used to measure affinity for HAPTl and LAPTl (Table 6.5).
Compound K i ( p M )P2 HAPTl LAPTl
DB75 2.3 71.2* No inhibition at 100 pM*
DB 544 1.99 15.3* No inhibition at 100 pM*
DAPI 0.68* 26.6* 13.6*
Pentamidine 0.26* 0.0364* 56.7*
Table 6.5. Ki values of DB 75. DB 544 and DAPI for trvpanosome pentamidine transporters.
* Results H . de Koning, unpublished data.
DB 75 and DB 544 have a high affinity for P2 but show no affinity for LAPTl and limited 
affinity for HAPTl. DAPI also has a high affinity for P2. This compound however also has a 
relatively high affinity for LAPTl, Table 6.5 (H. de Koning. unpublished data). Further 
studies on the inhibition of adenosine transport via the P2 transporter using the oil-stop 
technique showed DB 75 and DB 544 have Ki values of 2.3 pM and 1.99 pM respectively 
(Figures 6.3 and 6.4).
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Figure 6.3. Inhibition of adenosine uptake bv DB 75. 
n = 3.
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Figure 6.4. Inhibtion of adenosine uptake by DB 544.
n = 3.
The above results suggest that of all three pentamidine transporters, DAPI, DB 75 and DB 544 
have the highest affinity for, and are likely to enter the cell mostly via P2. DB 75 and DB 544 
appear to have no interaction with the low affinity, high capacity transporter LAPTl. Their
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moderate affinity for HAPTl could contribute to their uptake, however this transporter is very 
low capacity and as such would be expected to contribute very little to their internalisation at 
the concentrations used in this assay, DAPI has moderate affinities for botli HAPTl and 
LAPTl, which could compromise its ability to be useful in this assay.
6.2.2 Development of Fluorescence
6.2.2.1 DAPI
Fluorescence developed in TbATl and ATbatl cells in the presence of DAPI as shown in 
Table 6.6.
Incubation 
time (min)
1 pM DAPI 10 pM[DAPI
TbATl ATbatl TbATl ATbatl
0 + + + +
5 + + ++ ++
10 ++ ++ ++ ++
Table 6.6. Development of fluorescence in the presence of DAPI.
+ : visible fluorescence 
++ : strong fluorescence
Fluorescence developed at the same rate in cells that had a fully functional P2 transporter and 
in those lacking P2. This may reflect the transport of DAPI by the pentamidine transporters, 
HAPTl and LAPTl for which it has moderate affinities, or other modes of uptake.
The failure of DAPI to differentiate between sensitive and resistant cell types led to this 
compound being dropped as a potential agent in the development of a drug resistance test.
6.2.23 DB 75
In order to optimise the concentration of DB 75 to be used in the assay, the development of 
fluorescence in the presence of 1 pM, 10 pM or 100 pM DB 75 was followed. The results are 
shown in Table 6.7.
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Incubation 
time (min)
1 pM 10 pM 100 pM
TbATl ATbatl TbATl ATbatl TbATl ATbatl
0 - - + - +
5 - - + - + *•
10 + - + - + 4-
15 + - + - 4- 4-
20 4- + + + 4- 4-
Table 6.7. Development of fluorescence in the presence of 1.10 or 100 pM DB 75.
+ : fluorescence 
- : no fluorescence
Fluorescence developed at different rates in wild type and knockout cell lines in the presence 
of 1 pM, 10 pM and 100 pM DB 75. At 1 pM, fluorescence developed more slowly in the 
resistant cell line than in the sensitive cell line. The 10 pM concentration, however, gave a 
clearer and longer window between the development of fluorescence in the different cell lines 
(20 minutes for fluorescence to emerge in ATbatl lines compared with instantaneous 
appearance of fluorescence in wild type), A concentration of 100 pM DB 75 gave a shorter 
time difference in the development of fluorescence between the sensitive and resistant cell 
lines, and also had very high levels of background fluorescence, making it more difficult to 
distinguish fluorescing cells. A concentration of 10 pM was used for all subsequent 
experiments
The development of fluorescence in the presence of 10 pM DB 75 was followed over 10 
minutes in all the cell lines described. The results are shown in Table 6.8.
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Incubation 
time (min) TbATl ATbatl P PBR 247 247 mr 386 386 mr
0 + - + - - - - -
1 + - - +/- * - - -
2 + - + - +/- * - + -
5 + - + - +/- * - + -
10 + - + - + “
Table 6.8. Development of fluorescence in the presence of 10 pM DB 75.
* Between 50 and 90 % o f  cells fluoresced in these samples. This is addressed in the text and appears to relate to 
the presence o f  stumpy forms.
+ : fluorescence 
- ; no fluorescence
None of the resistant cell lines, all of which lack P2 activity, developed fluorescence over the 
10 minute time period. There was, however, a notable variation in the timing of fluorescence 
in the sensitive cell lines. The TbATl and the T equiperdum P cell lines both developed 
fluorescence immediately. The drug sensitive 247 and 386 cell lines took longer, developing 
fluorescence after 1 or 2 minutes incubation respectively.
The difference m the development of fluorescence in sensitive cell lines will be an important 
variable to note when developing this test for use in the field. The assay will have to allow 
long enough to account for these strain differences and reduce the possibility of false 
negatives. However, the duration of incubation must discount the possibility of fluorescence 
developing in resistant cell lines creating a wisely positive result. It will be important to assess 
a large number of cell lines to identify a reliable window allowing accurate diagnosis of P2 
status and resistance. Based on the above data however, a 2-5 minute incubation time would 
be appropriate for identifying resistant and sensitive cell lines.
The observation that not all of the cells fi-om the drug sensitive 247 cell line fluoresced, even 
though this was a clonal cell line, was also seen in subsequent experiments with the dmg 
sensitive 386 cells, which are also clonal. Closer examination of blood smears revealed that, in 
murine infections, both 247 and 386 undergo cyclical parasitaemias (unlike T brucei 427 and 
T. equiperdum derived lines), which result in fluctuating ratios of short stumpy cells (ss) to 
long slender cells (Is). Morphological examination of wet smears found that the ss cells, which 
are differentiated for survival in the tsetse fly, only began to develop fluorescence after 20
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minutes of incubation, whereas the Is cells, the proliferative bloodstream form, developed 
fluorescence quickly.
T. brucei 427 ss forms have been shown to have down regulated P2 transport activity (H de 
Koning, unpublished data). This is perhaps because this transport function is not important in 
the subsequent procyclic form, the stage present in the midgut of the Tsetse fly. Studies with 
procyclic form 386 and 386 mr cells, showed that these cell types did not develop fluorescence 
at all over a 20 minute incubation, (Table 6.9), indicating that these lines may not express a 
functional P2 transporter
Incubation 
time (min)
Long slender cells Short stumpy cells Procyc ic cells
247 386 247 386 386 386 mr
0 - - - - - -
1 + - - - - -
2 + + - " - -
5 + + - " - “
10 + + - - - -
20 + + + - - -
Table 6.9. Development of fluorescence in different life cvcle stages and mixed Is and ss 
bloodstream infections with DB 75.
+ : fluorescence 
- : no fluorescence
6.2.2.3 DB 544
DB 75 is currently undergoing trials for FDA approval of its use against Pneumocystis carinii 
pneumonia. For this reason the decision was made to test a very similar, fluorescent 
diamidine, DB 544, rather than introduce potential novel uses of DB 75 that might, m some 
way, add complexity to the decision process.
The development of fluorescence in the presence of 10 pM DB 544 was measured in all the 
cell lines described. The results are shown below (Table 6.10).
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Incubation 
time (min) TbATl ATbatl P PBR 247 247 mr 386 386 mr
0 + - + - - - - ”
1 + - + - + - + -
2 + - + - + - + -
5 - + - + + + “
10 + - + - + + + +
Table 6.10. Development of fluorescence in the presence of 10 pM DB 544.
+ : fluorescence 
- ; no fluorescence
Fluorescence develops more quickly in the 247 mr and 386 mr cell lines in the presence of 
DB544 than in the presence of DB 75. There is still a time difference between the 
development of fluorescence in the sensitive and resistant cell lines, but it is not as long as that 
for DB 75. Because of this, DB 75 would be a better choice for using in a field application.
As in DB 75, short stumpy forms o f247 and 386 did not develop fluorescence in the presence 
ofDB 544 over 10 minutes.
A time course for the development of fluorescence in the presence of DB 544 in TbATl and 
ATbatl cells was acquired. The results are shown in Figure 6.5. Fluorescence develops in the 
sensitive cells almost immediately, but is only just visible on close examination in resistant 
cells at ten minutes. This leaves a window of at least ten minutes in which it is possible to 
differentiate between arsenical sensitive and resistant cell lines by the presence or absence of 
fluorescence. Isolated points of fluorescence wem visible among the ATbatl cells at all time 
points, but examination under phase contrast revealed this to be confined to dead cells.
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6.2.3 Blocking the Development of Fluorescence with Adenosine and Pentamidine
Fluorescence is dependent on the uptake of compound through a functional P2 transporter. 
The delayed fluorescence in the sensitive strains demonstrates that there are further routes into 
the cells for the compounds, the most likely candidates being the pentamidine transporters. To 
further clarify the situation we attempted to block the development of DB 75 fluorescence by 
pre-incubating cells for 30 seconds with an excess of inhibitory substrate before adding the 
fluorescent compounds. P2 uptake was challenged with 1 mM adenosine, and all pentamidine 
transporter uptake, including that by P2, was challenged with 1 mM pentamidine. The results 
are shown in Table 6.11.
Incubation 
time (min)
Incubation with 1 mM adenosine Incubation witli 1 mM Pentamidine
TbATl ATbatl TbATl ATbatl
0 - - -
5 - - - -
10 4- - -
15 4-4- - - -
Table 6.11. Inhibition of DB 75 fluorescence with adenosine and pentamidine.
++ : fluorescence 
+ : weak fluorescence 
- : no fluorescence
1 mM pentamidine is able to completely block the development of fluorescence in the 
sensitive and resistant cell lines tested Mien pre-incubated with the cells for 30 seconds. A 
pre-incubation with 1 mM adenosine in TbATl cells results in a time lag before fluorescence is 
seen, which is similar to that seen in ATbatl cells without the pre-incubation (Table 6.7).
These data give further credence to the theory that the delayed development of fluorescence in 
cell lines lacking P2 transport activity could be due to uptake of the fluorescent compound via 
the pentamidine transporters, HAPTl and LAPTl. However, since pentamidine is also a 
dicationic molecule that interacts with DNA, this large excess of pentamidine may also be able 
to block fluorescence by competing with the fluorescent compound for binding sites in the 
DNA.
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6.2.4 Trvpanotoxicitv
The fluorescent diamidines were observed to be trypanotoxic. DB 75, DB 544, DAPI and 
diminazene aceturate (berenil) were all tested for toxicity against T. b. brucei 427 and TbATl 
and ATbatl cells in vitro. The results are in Table 6.12.
Compound
ICsoCuM)
T brucei 
427 TbATl ATbatl Resistance factor
DB75 0.033 0.0454 5.282 116.19
DB544 0.033 0.0344 1.77 51.53
DAPI 0.38 0.477 1.9 3.98
Diminazene 0.14 0.124 2.32 18.6
Table 6.12. Trvpanotoxicitv of pentamidine analogues. DAPI and diminazene aceturate. 
Resistance factor is derived from the difference in sensitivity between the TbATl and A T batl cell lines.
The very high resistance factor between TbATl and ATbatl cells for DB 544 and DB 75 could 
reflect their very high specificity for uptake by P2, whereas DAPI, which has moderate 
affinities for LAPTl and HAPTl has a low resistance factor. The high resistance fectors of 
DB 544 and DB 75, as compared to that for diminazene aceturate, is however inconsistent 
with separate observations that diminazene aceturate is only internalised through P2 (H. de 
Koning, unpublished data). An uptake assay for the TbATl and ATbatl cell lines for the 
uptake of radiolabelled diminazene aceturate over time shows a lack of uptake in the ATbatl 
cells that lack a functional P2 transporter (Figure 6.6).
As the DB compounds have been shown to be internalised in cells lacking P2, perhaps through 
the LAPTl and HAPTl transporters, in a three day toxicity assay their resistance fiictor would 
be expected to be lower than that for diminazene aceturate, which is apparently excluded by 
lack of transport. An as yet undetermined route of entry for diminazene aceturate, or an effect 
of the drug on the cell surface could explain the ^parent inconsistencies. For example, 
diminazene aceturate may adhere to plasma proteins and be internalised by endocytosis. 
Alternatively it could act on some part of the tiypanosome cell surface as pentamidine does to 
Ca 2+ pumps in the plasma membrane (Benaim et al. 1993). This would serve to decrease the 
resistance factor, even though all active transport has been stopped.
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Figure 6.6. Uptake of berenil in TbATl and ATbatl.
Uptake o f  20 pM  berenil over time. Bars indicate standard deviations, n = 3.
6.3 Discussion
Drug resistance, particularly to melarsoprol, appears to be of increasing incidence in sleeping 
sickness-affected Aftica. Diagnostic tests for resistance are critical in enabling decisions on 
patient management with respect to treatment regimens to be made early. This chapter outlines 
a test that diagnoses drug resistance in four out of four parasite lines tested.
All laboratory-derived arsenical-resistant isolates that have been studied have altered P2 
activity (Burchmore and Barrett, unpublished). Moreover, if, as may be indicated in recent 
research (Matovu et al. 2001a; Matovu et al. 2001b), the loss of P2 is among the first events 
leading to drug resistance in the field, the test described above could provide health workers 
with a useful diagnostic tool. As a test for P2 function, and therefore resistance to arsenical 
and diamidine drugs, the rapid fluorescence technique described here is much more accessible 
than other techniques that have been suggested previously.
One previously suggested assay for P2 fimction involves the identification of point mutations 
in the TbATl gene by PCR followed by digestion of the product with Sfa N1 (Maser et al. 
1999). This is based on the observation that an arsenical-resistant cell line selected in the
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labomtoiy had 10 point mutations, one of which deleted a Sfa N1 digestion site and one of 
which created one. A similar pattern of point mutations has been identified in field isolates of 
T.b, gambiense taken fi-om relapse patients in north-western Uganda and northern Angola and 
in a T. b. rhodesiense strain fi-om south-eastern Uganda (Matovu et al. 2001b). Sfa N1 digested 
PCR products, run on a gel, exhibit distinct banding patterns depending on which Sfa N1 
restriction site is present.
This test confers no advantage over the fluorescence technique as far as the requirement of 
sophisticated equipment is concerned. In this assay a PCR machine and electrophoresis 
equipment would be needed along with cold storage for molecular reagents. Also, loss of 
fimction of P2 is not always associated with changes to Sfa NI digestion sites. 247 mr, for 
example, lacks TbATl altogether, and 386 mr and PBR have intact TbATl genes with no 
changes compared to their wild type parent strains that have lull P2 activity. Loss of 
transcription of the gene appears to underlie the loss of function phenotype in these cases. A 
test based on changes in this single TbATl restriction site would therefore not be able to firmly 
diagnose drug resistance in these cell lines. It is likely that many different mutations, leading 
to altered P2 function, could emerge in the field as well as the laboratory. The fluorescence 
test measures the loss of fimction phenotype regardless of particular genotype.
Another option for a drug sensitivity assay is the culture of cells firom infected patients in vitro 
followed by an in vitro drug sei^itivity test. However, T b. gambiense^ isolated fi-om the field, 
is very difficult to grow in vitro. Cells must first be established in an experimental animal and 
then adapted for in vitro culture. This is a time consuming practice taking weeks to derive 
reliably growing stocks, which is prone to failure (Matovu et al. 2001a). The rapid 
fluorescence test has the advantage of not relying on any specific change to the TbATl gene, 
the measure of this test being for fimctional expression of P2, regardless of what events may 
have led to the loss. This technique is also very sensitive, requiring only very few 
trypanosomes for diagnosis. Thus, in terms of speed and sensitivity, it is far superior to any 
other tests that have been proposed to date.
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63,1 Development of the Rapid Fluorescence Test for Arsenical Resistance for use in the 
Field
In spite of the advantages of the rapid fluorescence test for arsenical resistance there are 
several challenges to be overcome in the development of this test for the field, not least of 
which is access to a fluorescence microscope. Only larger field hospitals may have the 
resources necessary to work with a fluorescence microscope. This means that samples will 
have to be collected and then transported to another site for diagnosis. It may be possible to 
develop a technique for fixing the trypanosomes after exposure to the fluorescent diamidine 
(live cells are required to show active transport of the diamidine). Slides could then be 
transported and assessed for fluorescence. While a fixing procedure followed by transport 
would reduce the speed of diagnosis, this assay would remain faster than the alternatives 
outlined above.
The manner of fixation of cells exposed to fluorescent marker is vitally important. On fixation, 
cells, regardless of their origin, have a tendency to become ‘leaky’. This would allow 
fluorescent compound to flood into, and associate with the DNA of all cells, sensitive or 
resistant, resulting in false diagnosis of resistant cells as sensitive. This could be overcome by 
adding a large excess of fixative to the cells to greatly dilute the fluorescent diamidine or by 
adding an anionic ‘sponge’ to the buffer, after a period of incubation, to soak up excess 
diamidine, e.g. herring sperm DNA or poly-aspartic acid. Both of these methods could be used 
in conjunction with centrifijging the cells through an oil layer after incubation to separate them 
firom the flee diamidine in solution.
Moreover, recent advances in microscopy technology should make it possible to design and 
construct field microscopes suitable for fluorescence work. It may be possible to use a car 
headlamp or even sunlight as a light source with filters to produce the correct wavelength, or a 
light emitting diode (LED) of the appropriate wavelength, eliminating the need to transport 
samples to another location. Recent advances in LED technology have led to the development 
and marketing of LEDs that emit light of wavelengths appropriate for the test developed here. 
This would mean samples could be assessed in situ and the appropriate treatment could begin 
at once.
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Using a fluorescence-adapted field microscope in conjunction with a specially developed slide 
designed to capture trypanosomes fi-om a blood sample could also resolve another potential 
problem, namely that of low parasitaemias which are often presented in T. b. gambiense 
infections. The low parasitaemias presented means that mini-anion exchange chromatography, 
as used in routine diagnosis, will also be required for isolating trypanosomes for the test. As an 
alternative, it may be possible to capture trypanosomes on a slide coated with an anionic 
polymer. Since trypanosomes are positively charged at pH 8 they will stick to the negatively 
charged polymer while erythrocytes (negatively charged at pH 8) will not. The blood cells 
would then be washed off and the trypanosomes incubated with fluorescent compound (Figure 
6.7).
Blood sample dropped 
onto a coated slide.
Blood washed o ff  to leave 
trypanosomes
Live trypanosomes 
bathed in dye.
Trypanosomes washed 
in buffer (+ hsD NA )
Fixed and mounted.
Figure 6.7. Potential set u p  for the Rapid Fluorescence Test for Drug Resistance.
hsDNA = Herring Sperm D N A , could be added at this point in order to act as an anionic sponge, to capture
excess DB 75.
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The whole preparation could then be viewed wet, or fixed and mounted to be viewed at 
another time. Once assessed for fluorescence, this procedure has the additional advantage in 
that the wet or fixed cells can also be viewed under phase contrast. An experienced 
microscopist would at this stage be able to remove a further problem by identifying what 
proportion of the cells, if any, are short stumpy cell forms, and therefore would not fluoresce, 
possibly due to a lack P2 transport activity, eliminating the possibility of a falsely positive 
result for drug resistance.
On a final note, this test, and the equipment described, has the potential to be adapted for the 
diagnosis of drug resistance in many organisms as well as in cancer cells.
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This project aimed to investigate the potential of the P2 purine transporter as a 'gateway' for 
drug entry and its role in resistance to trypanocidal drugs. The first aim was pursued by 
connecting the primary substrate recognition motif of the P2 transporter, H2N-C(Ri)"N(R2), 
to a moiety which was potentially toxic to the trypanosomes. It was anticipated that the 
recognition motif would allow the toxic compound to be intemalised specifically by the 
trypanosomal cells, reducing the potential toxicity for the mammalian host.
Most rational drug design relies upon designing inhibitors of parasite-specific targets, which 
differ sufficiently fiom mammalian analogues to confer specificity. The majority of these 
potential dmg targets are, however, inside the parasite cell, and this necessitates their entry 
into the parasite cell in order for them to hit their appropriate target. Their entry could be 
achieved by designing a lipophilic compound that can cross any cell membrane including that 
of the mammalian host. There is, however, a drawback to this approach in that, although toxic 
or inhibitory compounds can be designed to a target specific to the parasite cell, a compound 
that has access to any cell increases the risk of toxicity to host cells.
The approach to dmg design used in this project involved targeting toxic substances 
specifically to the trypanosomes by exploiting the action of a parasite membrane transporter 
with a high affinity for a particular substrate, and a recognition motif for that substrate unlike 
any in mammalian cells. The P2 transporter is ideal for this approach to dmg design (Hasne & 
Barrett 2000) due to its high affinity for substrates carrying the recognition motif, the lack of 
any similar motif on mammalian purine transporters, its natural substrates being at very low 
concentrations within the bloodstream of the host and its likely ability to internalise substrate 
against a concentration gradient (de Koning & Jarvis 1999).
The toxic moieties used included polyamine analogues, nitrofurans and nitroimidazoles and 
HIV gpl20 binding mimetics, as well as compounds selected from a database. The P2 
recognition motif was added in the form of either a melamine or a benzamidine group, or, for 
all of the database compounds except Distamycin A, was present in the form of a guandine 
group.
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The results from the database compounds indicated that the guanidine group could not act as a 
substrate for P2. The only compound in this group to show any interaction with the P2 
transporter was Distamycin A, which carries an amidine group. The HIV gpl20 binding 
mimetics 509 and 510 also carry a guanidine motif, and these have up to 24-fold less affinity 
for the P2 transporter than their benzamidine analogues, again reflecting the loss of affinity 
that guanidine residues confer (Table 4.2). In these compounds it is possible that the loss of 
affinity is attributed to the spatial configuration of the primary P2 recognition motif with 
respect to the n orbitals of the benzene ring.
High affinity binding to the P2 transporter requires an aromatic system on the substrate (de 
Koning & Jarvis 1999). It is proposed that the n-orbitals of the substrate stack with the tc- 
orbitals of an aromatic residue within the substrate binding site to increase the binding energy 
of the interaction and stabilise the bond. From results reported in this thesis, it also appears 
that the P2 transporter requires the primary recognition motif and the aromatic system to be in 
a planar configuration for optimal binding, as is reflected in the higher affinities for P2 in the 
planar benzamidine and melamine compounds as compared to the non-planar guanidine 
compounds.
All of the compounds that carried either a melamine or a benzamidine recognition motif were 
able to inliibit the uptake of adenosine via the P2 transporter. There are general patterns in 
their ability to inhibit P2 transport, with respect to their structures, as outlined below.
The polyamine analogues demonstrate an increasing affinity for P2, as measured by apparent 
Ki values, with an increase in the length of their central chain. This may reflect the amount of 
time a longer compound takes to traverse the cell membrane and for the transporter to 
reconfigure itself to receive another substrate molecule. The longer each inhibitor molecule is 
associated with the transporter and is blocking the uptake of the labelled substrate, the lower 
the Ki will appear. This means that a compound with a low affinity that travels across the 
membrane slowly may appear to have the same Kias a compound that has a high affinity but a 
faster turnover. In order to determine whether this is the case with these polyamine analogues, 
labelled compounds would be required to determine transport kinetics.
123
C hapter VIL G eneral Discussion.
Affinity for P2 is consistently greater in the majority of melamine compounds bearing one 
monomethylated or dimethylated melamine amine on their transport units than for their 
unmethylated analogues. It is possible that the methyl substitution of one amine group might 
increase the electron density in the compound’s 7c-system, which in turn could increase the 
contribution of ir-stacking interactions to the binding of the compound, whilst leaving one 
amine group open as the primary recognition motif for the transporter. The addition of any 
more methyl groups disrupts the P2 recognition motif and decreases affinity.
The benzamidine compounds in this study show greater affinities for P2 than most of the 
melamine bearing compounds. However, in vitro toxicity experiments for these compounds 
against TbATl and the P2 transport deficient ATbatl cell lines reveal no difference in toxicity, 
suggesting that the P2 transporter is not critical in the delivery of these compounds. There is a 
possibility that any difference in toxicity due to P2-specific uptake has been masked due to a 
difftision component.
Further studies using analogous benzamidine- and melamine-bearing compounds would 
further clarify the situation regarding a possible structural preference for the benzamidine 
group over the melamine group in P2 interactions. If this were to be the case, then future 
compounds would benefit fi-om carrying a benzamidine in place of a melamine.
Some compounds showed very high toxicities towards trypanosomes in vitro but most 
demonstrated moderate toxieities, and a few, most notably the database compounds and the 
nitroimidazoles, appeared to lack any toxicity in vitro.
Although many of the database compounds have therapeutic properties or uses, they were 
chosen on the basis of the presence of the P2 recognition motif, and they lack any trypanocidal 
activity in vitro. The results also show that nitrofiarans are generally much more toxic to 
trypanosome cells than the nitroimidazoles. The activities of these compounds are related to 
the reduction potential of their nitro groups. As nitrofurans are more easily reduced than 
nitroimidazoles, their different redox potentials could explain the differences in their 
respective toxicities, although this could also increase host toxicity.
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The melamine-bearing compounds showed increasing toxicities corresponding to increasing 
méthylation of the melamine amines (Chapters III and IV). None of the compounds, 
methylated or unmethylated, showed any difference in toxicity towards a ATbatl (P2 
knockout) cell line, which would indicate that P2 is not important in the uptake of these 
compounds or in their toxic effects. In v/vo, however, the compound 744 was able to clear or 
delay the development of infections whereas its monomethylated analogue, 745, had no 
influence on parasitaemia (Table 4.4). This lack of in vivo activity in the methylated 
compound 745 indicates that méthylation, by decreasing toxicity, has opposite effects in vivo 
and in vitro, which could be related to either an influence on uptake or interactions with 
intmcellular targets.
744 represents a potential lead compound in the search for new trypanocides. Successful early 
and late stage animal trials have been conducted (Reto Brun, Swiss Tropical Institute, personal 
communication), and further work is needed on this compound to assess its mode of action 
and its usefulness as a trypanocidal drug in vivo.
Although 744 is clearly very active in vivo at therapeutic levels, there remains concern about 
its mode of action, in that the reduction of the nitrofuran group by mammalian cells could 
result in damage to host cells. One way of potentially avoiding this host toxicity would be to 
target the toxic moiety even more specifically to the trypanosome cell. There is evidence firom 
this study that benzamidines interact with P2 with greater affinity than melamine-bearing 
compounds, hi order to clarify the situation, it would be beneficial to synthesise test 
compounds bearing the nitrofuran group and a benzamidine group. If a benzamidine 
compound is scavenged more effectively by the trypanosome cells it could be administered in 
smaller doses, and would be less able to access mammalian cells, reducing the likelihood of 
host toxicity.
In order to investigate the respective uptake properties of benzamidine and melamine 
compounds with respect to the P2 transporter, we also require analogous compounds to be 
synthesised carrying a label of some kind, for example radioactivity or fluorescence. 
Furthermore, genes that eould code for membrane bound nutrient transporters are being 
identified through the trypanosome genome project. The substrate recognition motifs for these
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transporters remain to be described, but they could offer access routes, which could be 
exploited as parasite-specific gateways into the cell.
While the development of novel reagents that might enter trypanosomes via the P2 transporter 
is critical given the crisis in HAT chemotherapy, the concern that the loss of this transporter 
could lead to drug resistance is very real. Therefore a more detailed understanding of the role 
of the loss of P2 in drug resistance was required. The role of the P2 transporter in the 
development of Berenil resistance in a Z equiperdum strain \riiich had been reported to have a 
P2 transport component with greatly reduced affinity for adenosine was investigated. The gene 
encoding P2 transport activity, TbATl, was analysed in this cell line, T. equiperdum PBR, and 
its Berenil-susceptible parent cell line T, equiperdum P. TbATl fi-om both cell lines carried six 
nucleotide point mutations resulting in two changes at the amino acid level as compared to 
TbATl described m T. brucei 927. However, the sequencing results indicate that TbATl in T. 
equiperdum P exists as two alleles, one of which has two fiirther point mutations in the 
sequence (‘c’ allele). The T. equiperdum PBR cell line does not contain the ‘c’ allele, only 
having sequence corresponding to the first ‘a’ allele as found in T. equiperdum P.
The T equiperdum PBR cell line lacks any TbATl transcript detectable by Northern blot, 
which suggests that this loss of heterozygosity in T equiperdum PBR has resulted in a lack of 
transcription of the gene. This may have come about due to changes up or downstream of the 
open reading Jfiame, that regulate the expression of the ‘a’ allele. A subsequent loss of 
heterozygosity in the T equiperdum PBR cell line has resulted in a TbATl gene that is not 
expressed.
This loss of expression was expected to delete all adenine sensitive adenosine uptake fi-om the 
T. equiperdum PBR cell line. However, a low affinity adenine sensitive adenosine uptake 
component was identified through inhibition experiments. The nature of this transport 
component was not identified, but it was also identified in a ATbatl cell line and probably 
equates to the third adenosine transporter described in T evami by Ross and Bams, 1996.
The loss of P2 function has been related to resistance to the melaminophenyl arsenicals and 
the diamidine classes of trypanocidal compounds. The T. equiperdum PBR cell line and a
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ATbatl cell line, both of which lack P2 transport activity, show high level resistance to 
Berenil, and low level (four-fold and two-fold respectively. Table 5.5) resistance to arsenicals. 
The loss of P2 fonction in these cell lines has additionally been shown to only give low level 
resistance to the melamine and benzamidine compounds in this study. It would appear that, 
although these compounds where designed for uptake via P2, they have other routes of entiy, 
which reduces the likelihood of drug resistance developing rapidly through the loss of P2 
fonction to these compounds designed with melamine and benzamidine motifs.
Nonetheless, the loss of fonction of P2, appears to be a conserved feature of drug resistance m 
many laboratory derived cell lines, and under drug pressure, could be one of those most 
readily induced. Additionally, the loss of P2 transport activity has been linked to the 
development of drug resistance in the field. Although it appears that high levels of resistance 
to arsenicals are brought about through different mechanisms than P2 loss, it is possible that a 
two-fold loss in sensitivity is enough to allow parasites in the CNS to survive treatment and 
reinvade other tissues.
A test for loss of fonction of P2 would be a valuable tool for both research into the prevalence 
of the loss of fimction of P2 in the field and as a diagnostic tool for clinicians. The rapid 
fluorescence test described here identifies the loss of function of P2, regardless of the 
molecular basis for that loss, in four out of four parasite lines tested. As a test for P2 fimction, 
and therefore resistance to arsenical and diamidine drugs, the rapid fluorescence technique as 
described here is much more accessible than other techniques that have been suggested 
previously.
In conclusion, new trypanocidal compounds have been synthesised, one of which shows 
promise as a lead compound for drug development. These compounds have been shown to 
interact with the trypanosome P2 transporter, but do not rely solely upon the presence of this 
transporter for uptake into trypanosome cells, reducing the likelihood of the development of 
resistance to these compounds through the loss of the transporter. As loss of P2 has been 
identified as contributing to drug resistance in both laboratory derived cell lines and field 
isolates, a quick and simple test has been developed that is capable of identifying cells lacking 
the P2 transporter, and are therefore tolerant to pharmacologically relevant levels of diamidine
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and arsenical trypanocides. This simple test could be adapted for use in the field either for 
research purposes, or by clinical staff, with the aim of identifying patients with drug-resistant 
trypanosomiasis, and tailoring their treatment accordingly.
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Appendix I
Hepes
NaCl
KCl
CaCl
M gS04
N a 2 H P 0 4
D~glucose
Adjust to pH 7.4.
25 mM 
120 mM 
5.4 mM 
0.55 mM 
0.4 mM 
5.6 mM 
11.1 mM
PSG
PS Buffer
Na2HP0 4  (anhydrous) 13.48g
NaH2P04.2H20 0.78g
NaCl 4.25g
Final volume of IL in dd water at pH 8.
To 6 volumes PS add 4 volumes dd water with 1% glucose. Adjust to exactly pH 8.
Lvsis Buffer
Tris-ClpH8 
EDTA 
Sarkosyl 
Proteinase K
10 mM 
100 mM
1%
100 pg/ml
TAE
Trizma base 4.84 g
EDTA 0.372 g
Made up to 1 L in dd water adjusted to pH 8 with glacial acetic acid.
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Luria Bertani Medium (LB)
Bacto-tryptone 10 g
Bacto yeast extract 5 g
NaCl 10 g
Made up to 1 L, pH 7, sterilised by autoclaving.
20x SSC
Tri-sodium citrate 88.23 g
NaCl 175.32 g
PH 7-8, final volume 1 L.
Denhardt*s Solation
Bovine Serum Albumin 2 g
Ficoll 400.2 g
Polyvinylpyrolidone 2 g
Final volume of 100 ml, stored at -20oC.
20x Northern Gel Buffer
Na2HP04 0.36 M
NaH2PÛ4 0.04 M
Formaldehyde Gel-loading Buffer
Glycerol 50 %
EDTA pH 8 Im M
Bromophenoi Blue 0.25 %
Xylene cyanol FF 0.25 %
Blue Sample Loading Buffer
Bromophenoi Blue 0.25% 
Xylene cyanol FF 0.25%
Sucrose in water 40% (w/v)
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Sometimes, if you pay real close attention to 
the pebbles you find out about the ocean.
